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ABSTRACT OF DISSERTATION

PRECISION DRUG DELIVERY FOR
VANCOMYCIN EFFICACY AND SAFETY IN
CRITICALLY ILL PATIENTS
Vancomycin is the most commonly prescribed antibiotic for hospitalized patients.
Despite this fact and decades of clinical use, clinicians remain challenged to meet dosing
targets of this narrow therapeutic index drug as well as minimize the risks of therapy,
primarily nephrotoxicity. These concerns are magnified in critically ill patients given
their severity. Accordingly, in a series of five clinical studies, we sought to identify
optimal methods of vancomycin administration in critically ill patients to maximize
efficacy and minimize nephrotoxicity via three techniques: use of continuous versus
intermittent infusion, use of first-dose pharmacokinetic calculations to guide dosing, and
use of loading doses. (1) To identify the landscape in which vancomycin is being used,
we surveyed critical care pharmacists on self-reported vancomycin dosing practices.
Ninety four percent (94.2%) of pharmacists reported rarely using continuous infusions
and 89.2% rarely using first-dose pharmacokinetic evaluation. Loading doses were more
commonly used, but rationale for not using included lack of evidence and concern for
acute kidney injury (AKI). (2) Given this hesitation by clinicians, we performed a
retrospective cohort study of 449 critically ill patients with confirmed methicillinresistant Staphylococcus aureus (MRSA) pneumonia and/or bacteremia to test the
association of a loading dose of vancomycin (≥ 20 mg/kg) with clinical failure. While we
found no difference in clinical failure with use of a loading dose versus not, we also
found no difference in AKI. (3) Given that few clinicians reported using first-dose
pharmacokinetic evaluation to guide dosing, we performed a retrospective cohort study of
66 critically ill patients to test if first-dose pharmacokinetic evaluation was associated
with greater area-under-the-curve (AUC) target attainment at steady state. Indeed, firstdose pharmacokinetic evaluation increased AUC target attainment to 58.6% compared to
32.4% (p=0.033) in those patients who received empiric dosing. (4) Method of infusion
may also impact AKI risk in critically ill patients. We performed a systematic review and
meta-analysis of vancomycin continuous versus intermittent infusion in critically ill
patients. Eleven studies were identified which evaluated 2,123 patients. The risk of AKI
was found to be significantly reduced in continuous compared to intermittent infusion:
odds ratio 0.47 [95% confidence interval (CI) 0.34-0.65]. Additionally, continuous
infusions were associated with 2.63 greater odds (95% CI 1.52-4.57) of pharmacokinetic

target attainment compared to intermittent infusion. (5) In order to build from the theme
that continuous infusions offer more precise dosing at a lower risk of AKI, we conducted
a prospective observational study of 50 critically ill patients receiving continuous
infusion vancomycin that consisted of 239 dosing events and 124 vancomycin
concentrations. A population pharmacokinetic model was constructed to guide further
precision dosing in future studies of continuous infusion vancomycin. These findings
support further investigation of early pharmacokinetic evaluation and use of continuous
infusions to maximize the precision of vancomycin delivery to critically ill patients and
minimize the risk of AKI. Additionally, this work’s blueprint provides an approach for
future study of precision dosing of antimicrobials in critically ill patients.
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CHAPTER 1 INTRODUCTION
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1.1 Epidemiology of MRSA Infection and Vancomycin Use in Critically Ill Patients
Vancomycin is the most commonly prescribed antibiotic for hospitalized patients
in the United States, with reports demonstrating increasing use over time.1-4 Using
estimates of 36.5 million hospital stays annually in the United States,5 and approximately
100 days of therapy per 1000 patient-days,3,4 it has been estimated that over 3 million
patients receive vancomycin every year in the United States alone.6
Vancomycin is primarily used to treat Staphylococcus aureus, particularly
methicillin-resistant Staphylococcus aureus (MRSA). MRSA is responsible for a wide
variety of infections in hospitalized patients, including bloodstream infections,
pneumonia, device-related infections, skin and soft tissue infection, and others.7 In a
nationwide surveillance study of United States hospitals over a seven year period,
Staphylococcus aureus was responsible for 20% of nosocomial bloodstream infections,
with an alarming increase in MRSA isolates more than doubling from 22% to 57% over
the period from 1995-2001.8 In critically ill patients, MRSA bacteremia was associated
with significantly higher attributable mortality compared to methicillin-sensitive
Staphylococcus aureus (MSSA).9 S. aureus is isolated in approximately one out of every
five cases of ventilator-associated pneumonia, with approximately 56% MRSA isolates.10
Vancomycin was approved by the Food and Drug Administration (FDA) in
1958,11 yet despite additional antimicrobials garnering FDA approval, it remains one of
the most commonly used antibiotics for MRSA, particularly in critically ill patients. A
tricyclic glycopeptide, vancomycin is bactericidal by binding to D-alanyl D-alanine,
which subsequently inhibits synthesis and polymerization of N-acetylmuramic acid and
N-acetylglucosamine, long polymers that make up the peptidoglycan cell wall layer.12 In
2

national guidelines for a variety of conditions impacting critically ill patients, it remains
as a primary recommendation for empiric or definitive therapy for several conditions
when MRSA infection is suspected or confirmed, including: sepsis,13 pneumonia,14
meningitis,15 catheter-associated bloodstream infections,16 intra-abdominal infections,17
neutropenic fever,18 endocarditis,19 and skin and soft tissue infections,20 among others.
Other potential antimicrobials against MRSA have known limitations that may limit use.
Daptomycin is inactivated by pulmonary surfactant thus not suitable for treating
pneumonia,21 a common source of infection on the differential diagnosis for critically ill
patients with sepsis and unknown foci of infection. Limited data, particularly randomized
controlled trials, exist for ceftaroline in the above-mentioned conditions. Linezolid has
been compared to vancomycin, but meta-analyses suggest no benefit of linezolid in terms
of mortality, clinical response, or safety.22 In addition, the direct drug costs of these
therapies often far exceed vancomycin. Antimicrobial stewardship concerns have
curtailed use of other antibiotics against MRSA given limited alternative therapeutic
options available for widespread use against MRSA should vancomycin lose sufficient
activity against MRSA to be used for empiric therapy. As such, despite the challenges of
using vancomycin for MRSA infections, it remains the most common choice for empiric
or definitive antibiotic therapy for MRSA in most centers in the United States healthcare
system.
1.2 Need for Precision Vancomycin Dosing in Critically Ill Patients
Despite FDA approval for over 50 years, active investigation continues into the
optimal dosing, monitoring, and administration strategies for vancomycin, as evidenced
by a recent change in national guidelines from trough-based to area-under-the-curve
3

(AUC)-based dosing, a paradigm shift in how vancomycin is monitored in the clinical
setting.23 In particular, critically ill patients have arguably the greatest need for precision
dosing of vancomycin for several reasons. First, due to life-threatening infections present
in the intensive care unit (ICU) patient population, rapid and sustained attainment of
pharmacokinetic/pharmacodynamic (PK/PD) targets with antimicrobials likely offers
greater benefit in critically ill patients compared to less ill patient populations. Second,
vancomycin is already a known narrow therapeutic index drug, and critically ill patients
are known to have alterations impacting hydrophilic antibiotics such as vancomycin
including altered volumes of distribution (Vd) and clearance (CL).24 Finally, patients in
the ICU have multiple non-modifiable risk factors for acute kidney injury (AKI), and
severity of illness is an acknowledged risk factor for vancomycin nephrotoxicity.25 In
short, critically ill patients have the most to gain from precision dosing of vancomycin for
efficacy and the narrowest margin for error with nephrotoxicity.
1.3 AUC:MIC Ratio as the Pharmacokinetic/Pharmacodynamic Target
As mentioned, the most recent consensus statement for vancomycin dosing and
monitoring recommends a shift from trough-based dosing to AUC monitoring.
Specifically, an area-under-the curve to minimum inhibitory concentration (AUC/MIC)
ratio ≥ 400 is the recommended PK/PD efficacy target.23 A few caveats deserve mention
on this topic prior to proceeding. First, this AUC/MIC recommendation primarily
originates from in vitro and in vivo experiments,26-30 with some supporting observational
clinical data,31,32 and failure to attain this AUC/MIC ratio may be associated with the
emergence of MRSA resistance to vancomycin.33 Second, this AUC/MIC typically refers
to MIC as that determined by broth microdilution (BMD). Commercially available MIC
4

testing methods are highly variable, both among themselves and the reference BMD.34
Furthermore, given that the BMD MIC90 is reportedly ≤ 1 mg/L in most institutions,35
consensus guidelines recommend assuming an MIC of 1 mg/L unless otherwise known to
be higher.23 This simplifies the vancomycin dosing target in practice to a
pharmacokinetic target, rather than a PK/PD target. Third, although a change from
trough-based dosing to AUC-based dosing has been associated with reduced
nephrotoxicity,36 the upper limit of vancomycin AUC remains debated from the
standpoint of nephrotoxicity risk. A number of studies, including a meta-analysis, have
found AUC values slightly above 600 mg⸱hr/L as a critical threshold for additional
nephrotoxicity risk.37 Accordingly, the recommended pharmacokinetic target for clinical
use of vancomycin is 400-600 mg⸱hr/L.23
1.4 Specific Aims
Against this backdrop of evolving evidence of vancomycin use, my dissertation
work is aimed at studying three techniques to optimize the efficacy and safety of
vancomycin dosing in critically ill patients: loading doses, first-dose pharmacokinetic
evaluation, and continuous infusions.
1.4.1 Aim 1: To establish current dosing and monitoring practices regarding vancomycin
use in critically ill patients. This will be accomplished via an online survey of practicing
critical care pharmacists in adult critical care and sponsored by the pharmacy section of a
multidisciplinary critical care organization. We will aim to establish critical care
pharmacist self-reported compliance with the 2009 vancomycin guidelines as well as
other nuances of vancomycin dosing and monitoring,38 with particular survey items
addressing areas of interest to this dissertation, including loading doses, first-dose
5

pharmacokinetic evaluation, and continuous infusions, among others. We will also survey
clinical practitioners on a group of hypothesized best practices for vancomycin dosing in
critically ill patients that, while considered important by the research team, may not have
had sufficient space in vancomycin consensus documents to comment on. This
introductory study will serve to assess the clinical landscape of vancomycin dosing and
monitoring in critically ill patients in current times. Based on a survey of infectious
disease pharmacists from nearly 10 years ago,39 we anticipate non-universal adoption of
loading doses of vancomycin. This prior survey39 identified a critical need to uncover
clinician rationale for non-compliance with guideline recommendations, which we plan
to address by not only asking about a variety of clinical scenarios for loading doses but
also by asking pharmacists why they may not always use such an option. Commonly
noted clinician hesitations will be considered in our clinical design of aim 2 assessing
loading doses. Given the timing of the survey administration, we anticipate that few
institutions are early adopters of AUC-guided dosing and that few pharmacists report
using first-dose pharmacokinetic evaluation. Given the 2009 vancomycin guideline’s
recommendation that “continuous infusions are unlikely to substantially improve patient
outcome when compared with intermittent dosing”38 we also anticipate finding that few
pharmacists are using continuous infusions of vancomycin, which we anticipate serving
as important baseline preliminary data, and establishing the need for change efforts,
should we identify continuous infusions of vancomycin reduce AKI compared to
intermittent infusion.
1.4.2 Aim 2: To assess the clinical benefit of a vancomycin loading dose in critically ill
patients with MRSA infection. Optimizing vancomycin use in critically ill patients starts
6

with the first dose, and given the increased Vd in critically ill patients, it is highly likely
that critically ill patients require loading doses to produce sufficient serum concentrations
to meet identified AUC/MIC goals. The 2020 vancomycin guidelines offer that a loading
dose of 20-35 mg/kg actual body weight (up to 3,000mg) can be administered to critically
ill patients with suspected or confirmed MRSA infection in order to more rapidly attain
target serum concentrations; however, this recommendation is only supported by
moderate evidence (BII; B- moderate evidence to support a recommendation for or
against use, II- evidence from 1 or more well-designed clinical trials, without
randomization; from cohort or case-controlled analytic studies (preferably from more
than 1 center); from multiple time-series; or from dramatic results from uncontrolled
experiments).23 Producing clinical evidence of benefit is challenging in any condition, but
if there is a patient population of MRSA infections that would benefit from a loading
dose, critically ill patients would appear to be highly likely as they are most at risk of
poor outcomes from infection. In 2015, myself and another collaborator wrote a grant
proposal to the Critical Care Pharmacotherapy Trials Network for a randomized,
controlled trial of loading doses on pharmacokinetic target attainment and AKI, but valid
concerns were noted in the review process of the extremely narrow time window allotted
for informed consent in these situations of sepsis, where every hour delay in
antimicrobial therapy within the first six hours is associated with a 7.6% reduction in
survival.40 Additionally, the number of patients that would have to be enrolled to accrue a
sufficient number of patients with documented MRSA cultures, and thus any sufficiently
powered study of efficacy, would make the sample size infeasible. As such, it became
clear that the most likely way to study clinical efficacy of loading doses was destined to
7

be a cohort study. If we want clinicians to use loading doses, and if part of the reason
they tell us they are not (which will be assessed in Aim 1) is due to lack of clinical
efficacy data, then it is imperative to provide this evidence.
1.4.3 Aim 3: To compare an approach of first-dose pharmacokinetic evaluation with
empiric dosing of vancomycin on AUC target attainment at steady state in critically ill
patients. Even though we now have clear guidance on the AUC goal of 400-600 mg⸱hr/L,
it was clear to myself and practicing colleagues in the critical care units that our empiric
approach to dosing vancomycin was often insufficient. Whenever vancomycin
concentrations were assessed at steady state, we commonly found trough or AUC values
outside of our target range. While nomograms of varying accuracy for vancomycin have
existed for years, what could represent more of a personalized approach to dosing than
assessing serum concentrations after a single dose and using a patient’s own
pharmacokinetic response to develop more precise future dosing regimens? This
approach of first-dose pharmacokinetic evaluation, indeed, has been studied for
aminoglycosides41 and incorporated into clinical practice in certain scenarios. In revising
our institution’s vancomycin dosing guidance, use of first-dose pharmacokinetic
evaluation was added as an approved option for pharmacists dosing vancomycin, and
particularly adopted in the medical ICU. The first-dose pharmacokinetic evaluation
concept has previously been evaluated to a limited extent in adult and pediatric
populations with mixed results.42,43 As they relate to vancomycin, prior studies evaluated
target attainment as trough rather than the currently recommended AUC. Accordingly, no
data exist on whether first-dose pharmacokinetic evaluation of vancomycin improves
AUC target attainment at steady state. Given our institution’s stance as an early adopter
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of AUC-guided vancomycin dosing, unique pharmacy practice model, and history of a
robust therapeutic drug monitoring program, we are primed to study this issue assessing
utility of first-dose pharmacokinetic evaluation, particularly in a targeted population of
critically ill patients with wide variability in pharmacokinetic alterations. Following study
of loading doses and first-dose pharmacokinetic evaluation, we will turn attention to the
method of administration and focus on infusion strategy as a mechanism for precision
dosing and maximizing safety.
1.4.4 Aim 4: To perform a systematic review and meta-analysis on the risk of AKI in
critically ill adults with continuous versus intermittent infusion of vancomycin. As noted
earlier, AUC values routinely above 600 mg⸱hr/L have been associated with
nephrotoxicity.37 Given their correlation, it is no surprise that vancomycin trough and
peak concentrations have similarly been associated with nephrotoxicity to some
extent.44,45 Data from animal models suggest that AUC or Cmax, but not trough, drive the
nephrotoxicity of vancomycin as assessed by urinary kidney biomarkers of injury kidney
injury molecule-1 (KIM-1) and osteopontin.6 Furthermore, in the same animal model, the
previous investigators also showed that equivalent vancomycin doses given less
frequently (once or twice daily administration, thus higher peak levels of the drug,
compared to three or four times daily), showed higher levels of urinary KIM-1.46
Vancomycin’s nephrotoxicity has long been known, but the precise mechanisms
of toxicity remain debated.25 One proposed mechanism of toxicity includes disruption of
mitochondrial function and production of reactive oxygen species, particularly in the
proximal tubule cells of the kidney.47 Supporting this hypothesis, multiple antioxidants
have shown promise of reducing vancomycin nephrotoxicity in pre-clinical studies.48
9

Secondly, vancomycin is filtered at the glomerulus and is both secreted and reabsorbed
by the proximal tubule cells.49,50 Drugs such as cilastatin have been shown to block the
reuptake of vancomyin by megalin, a major endocytic receptor on proximal tubule cells,
and subsequently reduce the nephrotoxicity from vancomycin in pre-clinical models.51
Third, a small series of biopsies from patients with confirmed vancomycin-associated
nephrotoxicity (and with elevated vancomycin troughs) revealed obstructive tubular casts
formed from non-crystal vancomycin aggregates in complex with uromodulin via an
unknown mechanism.52 Given these findings associated with vancomycin nephrotoxicity,
hypothesized mechanisms for reduced kidney injury with continuous infusions compared
to intermittent infusions may be related to the availability of drug for uptake into the
proximal tubule. By avoiding the high peak concentrations, either accessible to the
proximal tubule by the basolateral membrane or via reabsorption from the apical
membrane from the tubular lumen of the proximal tubule cell, this may keep the proximal
tubule cell’s exposure to vancomycin below some critical threshold that initiates a series
of events that alters mitochondrial function and cell proliferative response.53
Complementary or alternatively, these higher peak concentrations may contribute to a
saturation point that influences the cast nephropathy observed from human biopsy
studies,52 although less is known about this mechanism of toxicity.
Two smaller randomized controlled trials have previously studied continuous vs.
intermittent infusions, however, a number of factors have changed since these studies,
including vancomycin dosing targets (AUC vs. trough) as well as definitions for kidney
injury with classifications over the years focusing on more sensitive definitions rather
than a more severe state of kidney injury.54,55 A number of observational studies have
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been published comparing the two infusion strategies, however, meta-analyses have
either not focused on critically ill patients in particular56 or have applied meta-analytic
techniques that pooled unadjusted data from studies rather than considering the adjusted
estimates from individual studies.57 Given the smaller sample sizes of the pre-existing
studies, a meta-analysis in this scenario can not only increase the overall sample size of
patients considered, but also produces an informed prior estimate in terms of the effect
size for planning of future comparative trials. Building from the meta-analysis, the final
piece of the dissertation will focus on building a population pharmacokinetic model of
continuous infusion vancomycin in critically ill patients.
1.4.5. Aim 5: Build a population pharmacokinetic model of continuous infusion
vancomycin in critically ill adults. In preparing for future work comparing continuous
versus intermittent infusions of vancomycin, it will be critical to ensure that dosing
regimens are equally precise in both arms. While the focus of algorithms, nomograms,
and Bayesian software programs has been on intermittent infusions, much less focus has
been given to building models of continuous infusion vancomycin, presumably due to the
low frequency of use with which we anticipate observing in Aim 1. It is unknown if
vancomycin administered continuously differs in its pharmacokinetic behavior compared
to intermittent infusion. While a systematic review and meta-analysis revealed that
continuous infusions of vancomycin had greater pharmacokinetic target attainment and
lower variability compared to intermittent infusion,58 even with continuous infusions the
pharmacokinetic target attainment rates were as low as 47-57% in some studies of
critically ill patients.54,59 As with first-dose pharmacokinetic evaluation, we incorporated
continuous infusion administration of vancomycin as a dosing strategy while revising our
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institutional vancomycin guidelines, again used primarily in the medical ICU. A
prospective observational study of 50 patients will be planned based on guidance for
number of subjects in population pharmacokinetic studies with sparse sampling,60,61 and a
population pharmacokinetic model built from these data. Monte-Carlo simulations will be
performed with the hope of developing simplified dosing nomograms depending on the
findings from our population model.
These five aims will allow for assessment of three different strategies for the
difficult, but necessary task of precision dosing of vancomycin in critically ill patients.
These series of studies are advantageous in that not only are they immediately applicable
to direct clinical practice, but they will also serve as preliminary data for future study of
optimizing vancomycin delivery to critically ill patients, in particular, further
comparative effectiveness and urinary biomarker research between continuous and
intermittent infusions.
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CHAPTER 2 CURRENT VANCOMYCIN DOSING PRACTICES

This work has previously been published and is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 License:
Flannery AH, Hammond DA, Oyler DR, Li C, Wong A, Smith AP, Yeo Q,
Chaney W, Pfaff CE, Plewa-Rusiecki AM, Juang P. Vancomycin Dosing Practices
among Critical Care Pharmacists: A Survey of Society of Critical Care Medicine
Pharmacists. Infect Dis (Auckl). 2020 Sep 25;13:1178633720952078. doi:
10.1177/1178633720952078.
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2.1 Introduction
From 2009-2020, guidelines for vancomycin dosing were available through a
joint effort from the American Society of Health-System Pharmacists (ASHP), the
Infectious Diseases Society of America (IDSA), and the Society of Infectious Diseases
Pharmacists (SIDP).38 Despite availability of these guidelines and over 50 years of
clinical experience, much remains unknown regarding the optimal use of vancomycin in
clinical practice.62 A 2013 survey of infectious diseases pharmacists revealed discordance
between vancomycin practices and guideline recommendations, particularly regarding a
reluctance to use loading doses in seriously ill patients, to use actual body weight for dose
calculation in obesity, and to systematically monitor for complications such as
nephrotoxicity.39
The compliance of pharmacists and physicians with guideline recommendations
for vancomycin dosing and monitoring is important from an overall antimicrobial
stewardship perspective, but is of particular importance in the critical care setting for
several reasons. The complexities of the intensive care unit (ICU) patient population
introduce additional challenges to a complex drug. The acuity of the patient population
demands adequate pharmacokinetic-pharmacodynamic target attainment for serious, lifethreatening infections while minimizing the risk of nephrotoxicity for patients already at
risk of acute kidney injury and often simultaneously prescribed multiple other
nephrotoxins. Critically ill patients’ clearance of vancomycin could vary, from significant
decreases in acute kidney injury to clinically significant increases in the setting of
augmented renal clearance. Adjustments for other medical therapies, such as continuous
renal replacement therapy (CRRT) and other dialysis modalities, represent unique
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circumstances that may not be addressed by guidelines. Other ‘best practice’ items
related to vancomycin dosing in the critically ill are likely variable across ICU
pharmacists due to unique aspects of this patient population.
If any discordant areas of practice deviate in a substantial way from guideline
recommendations, understanding factors driving critical care pharmacists’ decisions to do
so are important to elucidate and represent cornerstones of implementation science
efforts. The purpose of this survey was to determine if this variability exists in an effort
to potentially inform future guideline recommendations and to reduce variability in
evidence-based practices. We sought to build on a prior survey of vancomycin use39 in
the following ways: 1. To perform a more recent survey of practice patterns given the
continuously updated literature on vancomycin since 2013, 2. To study under which
clinical scenarios ICU pharmacists may not adhere to guideline recommendations and
ascertain why, 3.) To characterize practice patterns regarding ICU-centric dosing
challenges that may not be addressed in consensus guidelines, and 4. To explore
respondent characteristics associated with compliance to guideline recommendations or
early adoption of certain vancomycin dosing practices.
2.2 Materials and Methods
2.2.1 Survey Design
A survey was developed by a pharmacist working group of the Society of Critical
Care Medicine (SCCM) Clinical Pharmacy and Pharmacology (CPP) Research and
Scholarship Committee in early 2017. This survey was approved by the University of
Kentucky Institutional Review Board as an exempt study.
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Survey questions were developed by the working group using the 2009
ASHP/IDSA/SIDP guidelines as a template.38 Once guideline recommendations were
addressed in the survey, the additional survey questions were created to capture
additional areas of what the authors considered “best practice” or areas where substantial
variability in practice was hypothesized to exist; for example, whether pharmacists were
alerted to initiation or discontinuation of renal replacement therapies to adjust dosing
accordingly. The survey was a 24-item questionnaire, with six general demographic
questions, eight vancomycin-related demographic questions regarding the practice site,
and 10 questions related to individual clinician’s vancomycin dosing practices
(Appendix 1).
A modified Likert scale was used: rarely (<10% of the time); sometimes (10-50%
of the time); often (51-90% of the time); and routinely (>90% of the time) was used for
questions of which a frequency of a particular action was inquired (e.g. how often a
clinician would recommend an intervention). A pilot survey was performed by 5 noncritical care pharmacists to establish face and content validity of the survey instrument.
Six critical care pharmacists not involved on the study team took the survey to estimate
time required for completion and provide any additional feedback or areas for
clarification. Verbal and written feedback from all pilot tests were incorporated into the
final survey by the research team. The survey required approximately 10-15 minutes for
completion.
2.2.2 Cross-Sectional Survey
Invitations to complete the survey were sent over e-mail twice, two weeks apart
during April of 2017. The survey was administered through and data collected using
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REDCap electronic data capture tools hosted at the University of Kentucky.63 Invitations
were sent out electronically via SCCM staff to all SCCM members of the CPP section,
which includes pharmacist and non-pharmacist members. Pharmacist members of CPP
practicing in adult critical care settings were specifically invited to take the survey and
represent the target population of interest. Non-pharmacist members, or pharmacists
practicing in a pediatric critical care setting, were asked not to respond to the survey.
2.2.3 Statistical Analysis
Data were analyzed with Stata (StataCorp. 2015. Stata Statistical Software:
Release 14. College Station, TX: StataCorp LP). Categorical data from the survey are
presented as proportions. Exploratory logistic regression analyses were undertaken to
evaluate factors associated with the following: selection of often or routinely (e.g. >50%
of the time) for loading doses for all six clinical scenarios examined, use of area-underthe-curve (AUC) as pharmacokinetic target parameter, and self-reported comfort with
AUC calculations (i.e. somewhat or extremely comfortable). Candidate predictor
variables identified a priori by the study team thought to influence vancomycin dosing
practices included: region, practitioner years of experience, hospital type, hospital size,
and ICU type. Due to complete separation of variables in some of the regression models,
a penalized maximum likelihood regression model was used with the firthlogit package in
Stata.64-66 Output from regression models are presented as odds ratios (OR) with 95%
confidence intervals (CI). Two-sided p-value <0.05 was considered statistically
significant.
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2.3 Results
2.3.1 Survey Response Rate
The survey was delivered to 2,305 SCCM CPP members (includes pharmacists
and non-pharmacists) via e-mail using the SCCM CPP section distribution list.
Approximately 1,500 of these members are pharmacists within the CPP section per the
SCCM demographic database. Based on internal demographic data from the section
indicating that approximately 100 pharmacists practiced in pediatric critical care, we
estimate that 1,400 of these pharmacists practiced in an adult ICU setting and would be
eligible for the survey. We received 364 responses, for an estimated response rate of
26%.
2.3.2 Respondent Demographics
Respondent demographics are presented in Table 2.1. Approximately half (48%)
of respondents were from urban academic medical centers. The two most frequent
responses for institutional bed size were 250-499 beds and 500-750 beds. The large
majority of respondents (>97%) were from the United States with relatively similar
representation from all major geographic areas. A majority of pharmacists participating in
the survey were clinical practitioners < 5 years (33%) or 5-10 years (29%) removed from
their terminal training. These pharmacists most frequently practiced in a medical (30%)
or mixed medical/surgical (32%) ICU. Over 90% of pharmacist respondents reported that
a pharmacist rounded with the primary or intensivist team at least five days per week.
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2.3.3 Vancomycin-Related Practices in Respondent Institutions
Practice site characteristics regarding vancomycin are presented in Table 2.2. The
most common responses regarding what percentage of Staphylococcus aureus isolates
were methicillin-resistant Staphylococcus aureus (MRSA) were either 20-39% (23% of
respondents) or 40-59% (34% of respondents). Vancomycin was routinely reported as
empiric therapy in hospital-acquired infections by 67% of respondents. Fifty-five percent
of respondents estimated the average duration of vancomycin use prior to de-escalation
when MRSA is not cultured as 48-72 hours. A large majority of respondents (85%)
reported that their institution reports the vancomycin minimum inhibitory concentrations
for MRSA in the medical record.
Approximately one-third of respondents (31%) reported their institution had no
formal pharmacy consult order (or pharmacy to dose protocol) to dose vancomycin.
Another 31% of respondents reported that pharmacists may deviate from the protocol as
written, which they sometimes do (10-50% of the time). The majority of pharmacists had
a protocol or other mechanism in place to order vancomycin serum concentrations (83%),
laboratory monitoring (e.g., such as a basic metabolic panel) (72%), or dose adjust
according to vancomycin serum concentration or renal function (78%); 18% of
respondents reported no formal mechanism for placing these orders, requiring they be
placed under a provider’s name pursuant to a verbal or written order.
Twenty percent of respondents reported a protocol for vancomycin dosing in the
setting of CRRT with a mechanism to alert the pharmacist that CRRT is being initiated or
discontinued; another 30% have a protocol with no mechanism to alert the pharmacist of
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CRRT initiation or discontinuation. Most respondents (60%) did not use sustained low
efficiency dialysis (SLED) at their practice site.
When asked which vancomycin monitoring and quality assurance programs were
offered at their institutions, respondents indicated low rates of participation with regard to
quality assurance for percentage of vancomycin dosing within a goal parameter (26%),
clinical decision support to identify acute changes in serum creatinine or urine output
(25%), and standardized definition of vancomycin-associated nephrotoxicity (7%).
2.3.4 Respondent Vancomycin Dosing Practices
Complete results are displayed in Table 2.3. With respect to scenario-based
questions regarding use of vancomycin loading doses, responses were mixed across
scenarios. The percentage of pharmacists reporting either routinely or often (51-90% of
the time) using a loading dose for the surveyed conditions were as follows:
meningitis/CNS infection (84%), septic shock (79%), infective endocarditis (75%),
pneumonia in a mechanically ventilated patient (69%), sepsis without shock (61%), and
pneumonia in a non-mechanically ventilated patient (54%). When respondents were
asked why they did not administer a loading dose at times for a critically ill patient, the
most common response was that their assessment of the patient did not meet the
definition of severely ill (40%), followed by lack of clinical outcome data supporting the
loading dose strategy (23%) and nephrotoxicity concerns (20%). Written comments by
survey respondents suggested other possible reasons, including physician concerns for
nephrotoxicity and logistics of having to compound the loading dose in the pharmacy
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versus using doses readily available in the patient care area from automated dispensing
cabinets.
Over 90% of respondents reported using actual body weight for loading doses and
maintenance doses in normal or underweight patients. For overweight or obese patients,
56% of respondents reported using actual body weight (41% used adjusted body weight)
for a loading dose and 45% of respondents reported using actual body weight (51% used
adjusted body weight) for maintenance dosing. The most commonly reported dose cap
for a loading dose was 2,000 mg (45%) followed by 2,500 mg (28%), while 2,000 mg
was the most commonly reported dose cap for maintenance dosing with the majority of
respondents (75%).
The majority of respondents reported rarely assessing post-loading dose
concentrations, two level kinetics following the first dose, and peak levels. The vast
majority (87%) of respondents reported using trough values while 13% reported using
trough and AUC. When using trough values, 24% of respondents report that doses are
held routinely pending evaluation of the level, while 64% report doses are held pending
evaluation only in the setting of suspected acute kidney injury.
Pharmacists most commonly (92%) reported administering vancomycin via
intermittent infusion with the majority of pharmacists rarely using continuous infusion.
Pharmacist perception of their comfort level with AUC calculations was variable with
intermittent infusion. The majority of respondents (62%) report being not at all
comfortable with AUC calculations for continuous infusions.
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In exploratory regression models, respondents from larger hospitals were overall
less likely than smaller hospitals to report consistently using loading doses often or
routinely in all six scenarios presented: 250-499 beds (OR 0.4, 95% CI 0.2-0.9), 500-750
beds (OR 0.4, 95% CI 0.2-0.9), and > 750 beds (OR 0.4, 95% CI 0.2-0.8) [reference
hospitals with < 250 beds]. Europe (OR 22.8, 95% CI 2.3-228.7) and Western US regions
(OR 3.6, 95% CI 1.5-8.6) were more likely to report using AUC as a target
pharmacokinetic parameter for vancomycin use. No predictors were identified for
reported comfort with AUC calculations.
2.4 Discussion
Compliance with clinical practice guidelines is influenced by many factors,
notably the quality of the guidelines themselves, users of the guidelines, and
implementation context.67 Critical care pharmacists were overall compliant with many of
the 2009 guideline recommendations assessed except for a few particular areas.
Specifically, we observed inconsistent use of a loading dose, dosing weight in obese
patients, and quality improvement efforts related to systematically monitoring
vancomycin-associated nephrotoxicity.
A survey of infectious disease pharmacist self-reported adherence to the 2009
guidelines was previously published in 2013.39 Key variations in infectious disease
pharmacist reported practices from 2009 guideline recommendations involved the
recommendations around loading doses in seriously ill patients (only 42% reported
always), use of actual body weight to dose obese patients (40% reported sometimes; 52%
reported always), and systematically monitoring nephrotoxicity with a standard definition
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to routinely identify and report vancomycin-associated nephrotoxicity (34% reported
never; 35% reported sometimes).39 The authors of this study noted it imperative to
discern reasons for noncompliance to the loading dose recommendation, particularly in
severely ill patients who may benefit and have altered pharmacokinetics.39 Our survey
builds on prior work with a larger and more diverse study sample and is unique by
focusing on adult critical care pharmacists, includes survey items regarding sources of
practice variation related to vancomycin in critically ill patients, and investigates reasons
for pharmacists not adhering to certain 2009 guideline recommendations.
Our survey also identified variation in compliance with loading dose
recommendations; however, some pharmacists report practicing differently in specific
scenarios. In particular, their assessment of severity of illness appears to be a large factor
in administering a loading dose. Although some respondents may consider an ICU patient
“severely ill” as the 2009 guidelines term it, this classification can be subjective.38 Lack
of clinical outcomes behind the 2009 recommendation for loading doses (IIIB
recommendation) and concerns of nephrotoxicity in an already at-risk patient population
are also commonly reported reasons for selectively administering loading doses.38
Concerns of nephrotoxicity with loading doses by physician colleagues were also noted
in the written responses from pharmacist respondents in this survey and identified as
potential barriers to routinely using loading doses.
There were similar discrepancies between using actual body weight for dosing in
obese patients between the two surveys, with a number of pharmacists in the current
survey reporting use of an adjusted body weight.39 The pharmacokinetics of vancomycin
are known to be an area of controversy in obese patients.68 Due to the hydrophilicity of
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vancomycin and the increase in adipose tissue associated with obesity, its volume of
distribution is somewhat increased in obese patients. In addition, various dosing weights,
including ideal body weight, total body weight, and adjusted body weight, have been
evaluated in estimating clearance of vancomycin with conflicting results.69 Given the
complexity of critically ill, obese patients and a lack of strong evidence for how to
optimally dose vancomycin in these patients, it is not surprising that our survey revealed
such practice variation.
In both our survey and that of Davis et al,39 there do seem to be opportunities
related to standardized definitions of vancomycin-associated nephrotoxicity and quality
improvement programs to track and monitor this complication. The possibility exists that
this is done within the context of antimicrobial stewardship programs and surveyed ICU
pharmacists may not be aware, but this was reported as similarly low in the survey of
infectious diseases pharmacists.39 Additionally, an opportunity may exist for more
institutions to implement CRRT alert triggers for pharmacists to increase or decrease
doses, as appropriate.
The majority of critical care pharmacists surveyed rarely employed continuous
infusion dosing of vancomycin. Interestingly, recent evidence suggests that continuous
infusions may be less nephrotoxic than intermittent infusions, particularly in critically ill
patients.56,70,71 Of paradoxical interest is that pharmacists were reportedly far less
comfortable with AUC calculations for continuous infusions than with intermittent
infusions, given the AUC calculations for continuous infusion are much simpler than for
intermittent dosing. The varying comfort level with AUC calculations in this survey
demonstrates the importance of educational efforts that will be needed to employ AUC24

guided dosing in ICU patients on a larger scale, as is recommended by the revised
vancomycin consensus guidelines recently published in May of 2020.23
Our exploratory analysis found that respondents from larger hospitals were
generally less likely to report consistent use of loading doses compared to respondents
from hospitals with < 250 beds. While the exact reasoning for this is unknown, it could
be due to a relatively smaller number of respondents from hospitals with < 250 beds
(15.1% of respondents) or perhaps improved compliance with protocols and guideline
recommendations in smaller hospitals from this survey. Additionally, our analysis
suggests geographic variation in early adoption of AUC to guide vancomycin dosing,
with greater adoption in Western United States and Europe at the time our survey was
administered. Pharmacist education is clearly required for AUC dosing and monitoring
given the reported comfort rates. Although the pharmacokinetic assumptions are fewer
and calculations easier with continuous infusion, this may simply represent the
unfamiliarity of critical care pharmacists surveyed with employing continuous infusions
due to the low frequency of use identified.
Our study has important limitations to acknowledge. Only SCCM CPP members
participated in the study; thus, reported behaviors from non-survey responders and nonSCCM CPP members may be different. This survey only inquired about self-reported
actions regarding vancomycin and may not reflect actual actions from clinicians in their
practice. Multiple respondents may have responded from the same institution, thus
biasing some reported metrics. Our response rate of 26% limited the number of
respondents that we were able to collect data from, however, our study is more than twice
as large as the prior study of vancomycin dosing practices.39 Although Europe was
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identified as using AUC more than others in this survey, there were few respondents from
Europe, which may only represent a few institutions and not be representative of
European practice. Finally, our survey was disseminated in the spring of 2017, and we
suspect additional centers have transitioned to AUC monitoring at this time given a signal
of increased safety in terms of kidney injury as well as anticipated (and actual)
endorsement of AUC guided dosing in recently released revised consensus vancomycin
guidelines.23,36,72 Although these revised guidelines have been published since our survey,
aside from recommending a change from trough-based dosing to AUC and no longer
directly recommending actual body weight in maintenance dosing for obesity, many of
the recommendations as they relate to our survey remain similar between the 2009 and
2020 guidelines.23,38 Table 2.4 compares relevant dosing considerations from our survey
between the 2009 and 2020 guidelines.23,38 Our data may serve as a benchmark in
evaluating uptake of consensus guideline recommendations, particularly against the
backdrop of showing a relatively low ‘early-adopter’ rate for AUC-guided dosing. In the
context of newly revised consensus guidelines, we also show continued room for
improvement with the guideline recommendation for loading doses, and demonstrate that
a small percentage of surveyed pharmacists are employing continuous infusion. Finally,
our survey also establishes the prevalence of important dosing concepts that may not be
presented as formal guideline recommendations yet may reflect best practices in dosing
vancomycin in critically ill patients, including electronic alerts for CRRT initiation or
discontinuation.
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2.5 Conclusion
Critical care pharmacists’ reported practices regarding vancomycin are largely consistent
with the 2009 vancomycin guideline recommendations. Important areas of variation
include use of loading doses, dosing weights in obese patients, and quality improvement
efforts related to systematically monitoring vancomycin-associated nephrotoxicity.
Further study in these particular areas may allow more definitive guideline
recommendations to help optimize vancomycin use in the critically ill.
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Table 2.1 Respondent Demographics
Practice Region
Midwestern United States
Southern United States
Western United States
Northeastern United States
Outside of United States
Institutional Setting
Academic medical center/urban
Community hospital/teaching/urban
Community hospital/non-teaching/urban
Other (including government and rural hospitals)
Institution Size
< 250 beds
250-499 beds
500-750 beds
> 750 beds
Current Level of Training
Current PGY2 specialty pharmacy resident (any specialty)
Practitioner less than 5 years out from terminal training
Practitioner 5-10 years out from terminal training
Practitioner more than 10 years out from terminal training
Other
Primary Location or Service
Cardiothoracic ICU
Emergency Department
Medical ICU
Mixed Medical/Surgical ICU
Surgical/Trauma ICU
Other
Pharmacists Physically Round with the Primary or Intensivist Team ≥ 5 days/Week
Yes
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Number (%)
111/364 (30.5)
109/364 (30.0)
74/364 (20.3)
60/364 (16.5)
10/364 (2.7)
174/364 (47.8)
89/364 (24.5)
44/364 (12.1)
57/364 (15.6)
55/364 (15.1)
119/364 (32.7)
99/364 (27.2)
91/364 (25.0)
35/364 (9.6)
121/364 (33.2)
104/364 (28.6)
99/364 (27.2)
5/364 (1.4)
20/364 (5.5)
20/364 (5.5)
109/364 (29.9)
115/364 (31.6)
49/364 (13.5)
51/364 (14.0)
332/364 (91.2)

Table 2.2 Practice Site Characteristics and Vancomycin-Related Demographics

Number (%)
Institutional Protocol Description and Pharmacist Adherence
Pharmacists must adhere to the protocol as written and may not deviate
8/364 (2.2)
Pharmacists may deviate from the protocol as written, but I rarelya do
36/364 (9.9)
Pharmacists may deviate from the protocol as written, which I sometimesb do
111/364 (30.5)
Pharmacists may deviate from the protocol as written, which I oftenc do
63/364 (17.3)
Pharmacists may deviate from the protocol as written, and I routinelyd do
34/364 (9.3)
No formal protocol exists in my primary practice
112/364 (30.8)
Pharmacist Authorized to Order
Vancomycin levels
303/364 (83.2)
Laboratory tests for monitoring (e.g., basic metabolic panel)
262/364 (72.0)
Dose adjustments based on vancomycin levels or renal function changes
283/364 (77.8)
Institutional Protocol for Vancomycin Dosing in Continuous Renal Replacement Therapy (CRRT)
Yes; but there is no mechanism to alert the pharmacist that CRRT is being
109/364 (29.9)
initiated or discontinued
Yes; and there is a mechanism to alert the pharmacist that CRRT is being
71/364 (19.5)
initiated or discontinued
No; and there is no mechanism to alert the pharmacist that CRRT is being
93/364 (25.6)
initiated or discontinued
No; but there is a mechanism to alert the pharmacist that CRRT is being
51/364 (14.0)
initiated or discontinued
Primary practice ICU does not utilize CRRT
40/364 (11.0)
Institutional Vancomycin Monitoring and Quality Assurance Programs
Quality assurance for percentage of vancomycin dosing regimens within goal target
96/364 (26.4)
parameters
Real-time clinical decision support to notify pharmacists of acute changes in serum
90/364 (24.7)
creatinine or urine output
Standardized definition of vancomycin-associated nephrotoxicity
27/364 (7.4)
None of these
159 (43.7)
Estimated Methicillin Resistant Staphylococcus aureus Isolates
20-39%
84/364 (23.1)
40-59%
122/364 (33.5)
60-80%
25/364 (6.9)
Other
32/364 (8.8)
Unknown/No specific antibiogram
101/364 (27.7)
Estimated Frequency of Empiric Vancomycin Therapy for Suspected Hospital-Acquired
Infections
Rarelya
6/364 (1.6)
Sometimesb
16/364 (4.4)
Oftenc
99/364 (27.2)
Routinelyd
243/364 (66.8)
Estimated Average Duration of Vancomycin Use Prior to De-escalation when MRSA is Not
Cultured
< 2 days (< 48 hours)
16/364 (4.4)
2-3 days (48-72 hours)
201/364 (55.2)
3-4 days (72-96 hours)
109/364 (30.0)
> 4 days (> 96 hours)
38/364 (10.4)
a
= < 10% of the time; b = 10-50% of the time; c = 51-90% of the time; d = > 90% of the time
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Table 2.3 Vancomycin Dosing and Monitoring Strategies

Frequency of Loading Dose Recommendation By Indication
Rarelya
Sometimesb
Oftenc
Routinelyd
Infective endocarditis
52/364 (14.3)
40/364 (11.0)
70/364 (19.2)
202/364 (55.5)
Meningitis/CNS infection
33/364 (9.1)
27/364 (7.4)
54/364 (14.8)
250/364 (68.7)
Pneumonia in a MV
51/363 (14.1)
60/363 (16.5)
75/363 (20.7)
177/363 (48.8)
patient
Pneumonia in a non-MV
94/363 (25.9)
74/363 (20.4)
71/363 (19.6)
124/363 (34.2)
patient
Sepsis with shock
40/364 (11.0)
38/364 (10.4)
68/364 (18.7)
218/364 (59.9)
Sepsis without shock
67/363 (18.5)
74/363 (20.4)
82/363 (22.6)
140/363 (38.6)
Pharmacist Reasoning When Choosing Not to Administer a Loading Dose
Lack of clinical outcome data supporting strategy
83/364 (22.8)
Nephrotoxicity concerns
73/364 (20.1)
Time required to infuse
13/364 (3.6)
The patient does not meet my definition of severely ill
146/364 (40.1)
Other
71/364 (19.5)
Most Commonly Used Weight for Dosing Vancomycin
Actual Body
Ideal Body
Adjusted Body
Weight
Weight
Weight
Loading dose for normal/underweight
353/361 (97.8)
5/361 (1.4)
3/361 (0.8)
patients
Loading dose for overweight/obese
201/361 (55.7)
12/361 (3.3)
148/361 (41.0)
patients
Maintenance dose for
341/361 (94.5)
9/361 (2.5)
11/361 (3.1)
normal/underweight patients
Maintenance dose for overweight/obese
162/361 (44.9)
16/361 (4.4)
183/361 (50.7)
patients
Most Commonly Used Dose Cap
2000 mg per
2500 mg per
3000 mg per
>3000 mg per
No cap/max
dose
dose
dose
dose
dose
Loading dose
164/362
102/362
61/362 (16.9)
8/362 (2.2)
27/362 (7.5)
(45.3)
(28.2)
Maintenance
273/362
43/362 (11.9)
10/362 (2.8)
2/362 (0.6)
34/362 (9.4)
dose
(75.4)
Use of the Following Strategies to Assess Vancomycin Exposure and Calculate Further Dosing
Rarelya
Sometimesb
Oftenc
Routinelyd
Collect a post-loading
322/361 (89.2)
29/361 (8.0)
3/361 (0.8)
7/361 (1.9)
dose level
Two-level kinetics after
277/361 (76.7)
63/361 (17.5)
14/361 (3.9)
7/361 (1.9)
first dose
Collect peak levels
325/361 (90.0)
21/361 (5.8)
6/361 (1.7)
9/361 (2.5)
Collect trough levels
9/362 (2.5)
18/362 (5.0)
32/362 (8.8)
303/362 (83.7)
Frequency of Doses Held Pending Level Evaluation When Trough Levels are Collected
Doses are held routinely (>90% of the time) pending level evaluation
87/362 (24.0)
Doses are held pending level evaluation only if kidney injury is suspected or
233/362 (64.4)
known
Doses are held rarely (< 10% of the time), even if kidney injury is suspected
42/362 (11.6)
or known
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Table 2.3 (continued)

Target Pharmacokinetic Dosing and Monitoring Parameter
Trough
314/363 (86.5)
AUC
2/363 (0.6)
Trough and AUC
47/363 (12.9)
Frequency of Vancomycin Dosing via Method of Administration
Rarelya
Sometimesb
Oftenc
Routinelyd
Intermittent
10/364 (2.8)
11/364 (3.0)
8/364 (2.2)
335/364 (92.0)
infusion
Continuous
342/363 (94.2)
16/363 (4.4)
3/363 (0.8)
2/363 (0.6)
infusion
Comfort Level Assessing Vancomycin Levels to Calculate AUC
Not at all
Somewhat
Somewhat
Extremely
comfortable
Uncomfortable
Comfortable
Comfortable
Intermittent
134/363 (36.9)
54/363 (14.9)
100/363 (27.6)
75/363 (20.7)
infusion
Continuous
223/362 (61.6)
59/362 (16.3)
49/362 (13.5)
31/362 (8.6)
infusion
a
= < 10% of the time; b = 10-50% of the time; c = 51-90% of the time; d = > 90% of the time; AUC= areaunder-the-curve; CNS=central nervous system; MV= mechanically ventilated
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Table 2.4 Comparisons Between 2009 and 2020 Vancomycin Consensus Guidelines
Relevant to Survey of Dosing Practices
Dosing Consideration 2009 Vancomycin
2020 Revised Consensus
38
Guidelines
Guidelines23
Monitoring Parameters “Trough serum vancomycin “Trough-only monitoring,
concentrations are the most
with a target of 15-20 mg/L,
accurate and practical
is no longer recommended
method for monitoring
based on efficacy and
vancomycin effectiveness.”
nephrotoxicity data in
(IIB)
patients with serious
infections due to MRSA”
(A-II)

Loading Dose and
Weight

“In seriously ill patients, a
loading dose of 25-30 mg/kg
(based on actual body
weight) can be used to
facilitate rapid attainment of
target trough serum
vancomycin concentration.”
(IIIB)

“In patients with suspected
or definitive serious MRSA
infections, an individualized
target of the AUC/MIC ratio
of 400 to 600 (assuming a
vancomycin MIC of 1 mg/L)
should be advocated to
achieve clinical efficacy
while improving patient
safety.” (A-II)
“In order to achieve rapid
attainment of targeted
concentrations in critically
ill patients with suspected or
documented serious MRSA
infections, a loading dose of
20 to 35 mg/kg can be
considered for intermittentinfusion administration of
vancomycin.” (B-II)
“Loading doses should be
based on actual body weight
and not exceed 3,000 mg.
More intensive and early
therapeutic drug monitoring
should also be performed in
obese patients.” (B-II)
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Table 2.4 (continued)
Maintenance Dosing
Weight

Continuous Infusion

“Vancomycin dosages
should be calculated on
actual body weight. For
obese patients, initial dosing
can be based on actual body
weight and then adjusted
based on serum vancomycin
concentrations to achieve
therapeutic levels.” (IIA)

“Continuous infusion
regimens are unlikely to
substantially improve patient
outcome when compared
with intermittent dosing.”
(IIA)
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“Initial maintenance doses of
vancomycin can be
computed using a population
pharmacokinetic estimate of
vancomycin clearance and
the target AUC in obese
patients. Empiric
maintenance doses for most
obese patients usually do not
exceed 4,500 mg/day,
depending on their renal
function.” (B-II)
“The pharmacokinetics of
continuous infusion suggest
that such regimens may be a
reasonable alternative to
conventional intermittentinfusion dosing when the
AUC target cannot be
achieved.” (B-II)

CHAPTER 3 EFFICACY AND SAFETY OF VANCOMYCIN LOADING DOSES
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3.1 Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen in
critically ill patients. In a nationwide surveillance study of United States hospitals,
Staphylococcus aureus was responsible for 20% of nosocomial bloodstream infections,
with an alarming increase in MRSA isolates more than doubling from 22% to 57% over
the period from 1995-2001.8 In critically ill patients, MRSA bacteremia is associated with
a 22.1% higher attributable mortality rate compared to methicillin-sensitive
Staphylococcus aureus (MSSA).9 S. aureus is isolated in approximately one out of every
five cases of ventilator-associated pneumonia, with approximately 56% MRSA isolates.10
Recent data suggest that inadequate attainment of a therapeutic vancomycin areaunder-the-curve (AUC) to minimum inhibitory concentration (MIC) ratio on days 1 and 2
of therapy in MRSA bacteremia is associated with treatment failure.73 Critically ill
patients commonly receive significant fluid resuscitation and experience fluid shifts from
the intravascular to the extravascular compartment, which increases the volume of
distribution (Vd) for hydrophilic drugs such as vancomycin.24,74 Accordingly, recently
updated consensus guidelines on vancomycin state that a loading dose of 20-35 mg/kg
actual body weight (not to exceed 3,000 mg) can be considered for critically ill patients
with suspected or confirmed MRSA infection in order to ensure rapid attainment of
appropriate serum concentrations.23 However, this recommendation is limited by
moderate strength of recommendation (B) and quality of evidence (II), and is primarily
based on pharmacokinetic outcomes rather than a documented clinical benefit.23
In a recent survey of practitioners regarding vancomycin dosing in critically ill
patients assessing self-reported consensus guideline compliance, use of loading doses for
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a variety of clinical scenarios was highly variable, with respondents often citing the lack
of evidence for the clinical decision to forego a loading dose, followed by concerns of
nephrotoxicity.75 Given that critically ill patients are particularly vulnerable to poor
outcomes from MRSA infection and exhibit altered pharmacokinetics of vancomycin that
may place them at risk of missing identified pharmacokinetic-pharmacodynamic targets,
they are logically the population to gain the most benefit from loading doses of
vancomycin. As such, we sought to determine if critically ill patients with MRSA
infection demonstrated improved clinical outcomes when receiving vancomycin loading
doses (versus not) in order to provide needed clinical data to augment the
pharmacokinetic outcomes previously assessed in studies of vancomycin loading doses.
3.2 Material and Methods
3.2.1 Study Design
This was a single center, retrospective cohort study of critically ill patients
admitted to any intensive care unit (ICU) from January 2008 to October 2016 within a
865-bed tertiary academic medical center that serves as a referral center for the state and
surrounding regions. Patients were included in the study if they had a positive respiratory
or blood culture for MRSA and had vancomycin initiated for MRSA during or up to 48
hours before an ICU admission. Exclusion criteria were as follows: weight ≥ 125 kg, any
MRSA culture other than from blood or respiratory source, <1,000 colony forming
units/ml or 1-2% MRSA on respiratory cultures, loading dose information missing (i.e.
from outside hospital), or if vancomycin was started > 48 hours prior to the ICU
admission. We elected to study pneumonia and bacteremia given the frequency of these
infections in critically ill patients and their relative degree of morbidity compared to other
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infections (i.e. skin and soft tissue) in an attempt to prognostically enrich the study for
patients that might clinically benefit from a loading dose of vancomycin.76 A weight of ≥
125 kg was excluded so as not to confound the assessment of loading doses on a
milligram per kg of actual body weight basis. Patients were classified into two cohorts
based on their initial vancomycin dose received: loading dose (≥ 20 mg/kg actual body
weight) or no loading dose (<20 mg/kg actual body weight).
The primary outcome was clinical failure, defined as a composite outcome with
similar definitions as prior studies of MRSA infection,77,78 which included: death within
30 days of first MRSA culture, blood cultures positive ≥ 7 days, white blood cell (WBC)
count >12 x103 /mm3 up to 5 days from vancomycin initiation, temperature >100.4°F up
to 5 days from vancomycin initiation, or substitution (or addition) of another targeted
anti-MRSA antibiotic such as daptomycin, linezolid, or ceftaroline. The primary outcome
was adjudicated in the order of the outcomes stated above, thus while some patients may
have had more than one definition of clinical failure, each patient was only classified
with one of the definitions based on the sequential order assessed.
Secondary outcomes included all-cause mortality in the ICU, time from
vancomycin initiation to ICU discharge, acute kidney injury (AKI) within 5 days of
vancomycin initiation as assessed by the serum creatinine component of the Kidney
Disease Improving Global Outcomes (KDIGO) criteria,79 first vancomycin serum trough
concentration value, and duration of vasopressor support, if applicable. Data were
extracted from the electronic data warehouse and manual chart review was performed on
all included patients to ensure integrity of the data. Data were collected on patients to
ensure comparability at baseline, including potential factors hypothesized by the
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investigators as being associated with receipt of a loading dose including severity of
illness assessments such as Sequential Organ Failure Assessment score (SOFA)80 and Pitt
bacteremia score (PBS),81,82 need for mechanical ventilation or vasopressor support at the
time of vancomycin initiation, hospital service (classified into medical or surgical ICUs),
history of kidney disease, and kidney function at the time of vancomycin initiation.
Vancomycin MICs were determined per Clinical and Laboratory Standards Institute
standards by broth microdilution via automated susceptibility testing methods with the
Phoenix™ Automated Microbiology System (BD Diagnostics, Sparks, MD, USA) from
1/2008 to 10/2013 and 4/2016 to 10/2016 and Etest (bioMérieux, Marcy l’Etoile, France)
from 11/2013 to 3/2016. Receipt of concurrent nephrotoxins within 5 days of receiving
the loading dose was classified as the receipt of any of the following: angiotensin
converting enzyme inhibitors, angiotensin receptor blockers, intravenous (IV) acyclovir,
aminoglycosides, amphotericin B, colistin, foscarnet, non-steroidal anti-inflammatory
drugs, polymyxin B, sulfamethoxazole/trimethoprim, IV tacrolimus, and
piperacillin/tazobactam. The study was approved by the institutional review board at the
University of Kentucky (#54961) with a waiver of informed consent given the study
design.
3.2.2 Statistical Analysis
Based on prior studies of MRSA infections suggesting clinical failure rates as
high as 41%,77,78 and assuming a higher percentage due to the requirement for critical
illness in our study, we anticipated a baseline clinical failure of 60%. In order to detect a
20% decrease in the clinical failure, we determined 97 patients were required in each
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group (194 patients in total) to achieve 80% power with an α = 0.05 for the primary
composite outcome.
Descriptive statistics were used to summarize categorical variables as percentages
and continuous variables as medians (interquartile range [IQR]). Independent samples
were compared using the chi-square test or Wilcoxon rank-sum test as appropriate. Given
the relatively high frequency of death anticipated from studying critically ill patients, we
analyzed time to ICU discharge from vancomycin initiation with a competing-risks
regression approach using the methods of Fine and Gray83 with death as a competing
event and displayed graphically with a cumulative incidence function. Analysis of
clinical failure by primary infection site (isolated bacteremia or pneumonia) between the
loading dose and no loading dose groups was a pre-planned secondary analysis.
Exploratory analyses of the primary outcome included the reconstruction of the loading
dose variable in quartiles rather than a dichotomous variable, and evaluation of initial
doses of ≥1,750 mg vs. <1,750 mg as hypothesized by other research groups to have
benefit.77 We built a multivariable logistic regression model for the composite outcome
of clinical failure using the following pre-specified variables with complete data present
identified by the study team with the potential to influence either the receipt of a loading
dose or outcome of clinical failure at the time the vancomycin loading dose was
administered: vancomycin initial dose (as a continuous mg/kg variable), age, sex, MRSA
culture site, chronic or end-stage renal disease, ICU service, day 1 maximum values for
WBC, blood urea nitrogen, serum creatinine, and temperature, SOFA score, need for
vasopressor support, or need for mechanical ventilation. The PBS was not included due
to presumed collinearity with SOFA and other variables included. Variance inflation
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factors were used to assess collinearity and ensure all variables were appropriate to retain
in the model. Statistical analyses were performed in Stata (StataCorp. 2019. Stata
Statistical Software: Release 16. College Station, TX: StataCorp LLC) and SAS (SAS
Institute Inc., Cary, NC, USA). Statistical significance was set at p< 0.05.
3.3 Results
As shown in Figure 3.1, 871 patients were identified as having an ICU admission
with a concurrent positive culture for MRSA during the specified ICU admission.
Following application of the exclusion criteria, 449 patients were available for analysis.
Of these patients, 103 (22.9%) received a loading dose while 346 (77.1%) did not. Patient
demographics for the cohort are shown in Table 3.1. The cohort consisted primarily of
patients on medical services with approximately half of MRSA cases isolated from
respiratory cultures. Approximately 3/4th of the cohort required mechanical ventilation
and 1/3rd required vasopressor support at the time of vancomycin initiation. Patients were
well-matched in terms of baseline characteristics between the two groups. Patients in the
loading dose group received higher initial doses on a mg (1500 [1250-1750] vs. 1250
[1000-1500]; p<0.001) and a mg/kg actual body weight basis (21 [20-22] vs. 16 [15-18];
p<0.001) compared to the no loading dose group. Patients classified as receiving a
loading dose tended to weigh less than patients in the no loading dose group (68 [61-85]
kg vs. 80 [66-97] kg; p<0.001). Only one patient received an initial vancomycin dose
greater than 2 grams. All patients were administered vancomycin via intermittent
infusion.
There was no difference in the percentage of patients experiencing clinical failure
between the loading dose and no loading dose groups (74.8% vs. 72.8%; p= 0.698), with
40

no significant difference between groups in any component of the composite outcome
(Table 3.2). No differences were noted between groups in any of the secondary
outcomes, including all-cause ICU mortality, AKI, or duration of vasopressor or
mechanical ventilatory support. The first serum vancomycin trough concentration was
slightly higher in the loading dose group, but this did not reach statistical significance
(15.6 [11.0-24.4] mcg/mL vs. 14.0 [9.5-21.0] mcg/mL; p=0.056). There were no
differences in WBC or maximum temperature in days 2-5 following the initiation of
vancomycin (Table 3.3, Figure 3.2). In a simple competing risk regression model with
death as a competing event, use of a loading dose was not associated with time to ICU
discharge from vancomycin initiation (Subdistribution hazard ratio 1.09; 95% confidence
interval 0.86-1.40). The cumulative incidence function is shown in Figure 3.3. In the
subgroup of patients with isolated MRSA bacteremia, there was no difference in clinical
failure between the loading dose and no loading dose groups: 30/34 (88.2%) vs. 63/80
(78.8%); p=0.232. Similarly, in patients with MRSA respiratory cultures (with or without
bacteremia), there were no differences between loading dose and no loading dose groups:
47/69 (68.1%) vs. 188/265 (70.9%); p=0.647.
In exploratory analyses of the primary outcome, the vancomycin dose (in mg/kg
actual body weight) was assessed in quartiles rather than a dichotomous variable and
there were no significant differences in the frequency of clinical failure (p=0.794; Table
3.4). Similarly, when initial doses of ≥ 1,750 mg were compared with doses <1,750 mg,
there was no difference in clinical failure between the two groups (p=0.485; Table 3.5).
In the adjusted multivariable logistic regression model, the first dose of vancomycin
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(expressed in mg/kg as a continuous variable) was not associated with clinical failure:
odds ratio (OR) 0.98 (95% confidence interval (CI) 0.91-1.06) (Table 3.6).
3.4 Discussion
This represents the first study to our knowledge to assess clinical outcomes
associated with vancomycin loading doses recommended by consensus guidelines in
critically ill patients with MRSA infection,23 and the largest study of vancomycin loading
doses in any patient population. While the ideal design to answer this clinical question is
a randomized controlled trial, given the literature that every hour delay in antibiotics in a
patient with sepsis is associated with a 7.6% reduction in survival,40 including similar
literature in S. aureus bacteremia specifically,84 obtaining informed consent during this
window for a definitively large study in critically ill patients is likely to hinder such a
trial ever being done, particularly for confirmed MRSA infection rather than all patients
receiving empiric vancomycin.
A randomized controlled trial of vancomycin loading doses in the emergency
department showed that a loading dose of 30 mg/kg vs. 15 mg/kg resulted in higher
trough values at 12- and 24- hours, but not by 36-hours, with no significant difference in
AKI or clinical outcomes between the two groups.85 Similarly, other observational
studies have shown an association between loading doses and higher target attainment of
initial trough values without increasing the risk of AKI,86,87 although improved target
trough attainment is not consistent across the literature.78,88 Similar to other studies, we
did not observe any increased risk of AKI with use of a vancomycin loading dose.85,86
Particularly with updated consensus guidelines recommending AUC assessment at this
juncture rather than trough assessment,23 the existing literature linking vancomycin
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loading doses to trough attainment as justification for use of a particular dosing strategy
deserves reevaluation. Thus, there is an increasing importance to evaluate clinical
outcomes regarding the decision to administer a loading dose.
One small cohort study found an association of vancomycin loading doses (≥ 20
mg/kg) with clinical response, as defined by survivors with a ≥ 30% reduction in WBC
count or C-reactive protein, or decline in fever over 48-72 hours; however, the number of
MRSA cases from the cohort studied was relatively small.78 In a larger study of MRSA
bacteremia, loading doses (≥ 20 mg/kg) were not associated with treatment failure;
however, in a post-hoc analysis where loading doses were reclassified as ≥ 1,750 mg, a
protective effect of loading doses was noted.77 In both studies, loading doses were not
associated with nephrotoxicity.77,78 Of note, critically ill patients were not the focus of
these prior studies, and ICU patients comprised approximately 25% of the cohort.77 Our
study did not find a benefit of loading doses on any of the distinct outcomes that we
included in the primary composite outcome, nor when assessed by site of infection as a
subgroup analysis. Similarly, there was no signal of benefit noted in the sensitivity
analysis examining quartiles of loading doses, the reclassification of loading doses as
1,750 mg or higher, or in the multivariable logistic regression model evaluating initial
dose on a mg/kg basis as a continuous variable.
As noted previously, a recent survey of vancomycin dosing practices in critically
ill patients revealed that a lack of clinical outcome data, concerns of nephrotoxicity, and
time delay of admixed custom doses from the pharmacy (in the case of a loading dose)
vs. pre-mixed drug from automated dispending cabinet limited application of loading
doses in all cases.75 Our data suggest loading doses of vancomycin do not increase the
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risk of AKI, even in critically ill patients with multiple risk factors for AKI. However, the
data also suggest no clinical benefit of loading doses even in confirmed MRSA infections
in critically ill patients, thus supporting the noted clinician hesitation. Indeed, given the
increase in mortality with every hour delay in antibiotic therapy,40,84 our study supports
the notion that therapy should not be delayed for dose customization to meet the specified
loading dose criteria. This finding not only applies to emergency departments, postanesthesia care units, and other ICU triage areas in resource-intensive healthcare settings,
but may also be a relevant consideration to care provisions in lower resource-intensive
settings where dose customization for loading doses may be limited. Although the
mechanistic explanation of our findings is less clear for patients with bacteremia, the
relatively poor ability of vancomycin to concentrate in pulmonary tissue, particularly
after a single dose, may explain the lack of difference in clinical outcomes observed in
our study.89 Additionally, considering the literature associating a delay in second dose of
antibiotics for patients admitted from the emergency department with sepsis with
outcomes including mortality,90 our study suggests that the initial, loading dose of
vancomycin may not significantly influence clinical outcomes in critically ill patients,
and a greater emphasis be placed on ensuring timely initiation of subsequent doses to
ensure appropriate efforts to attain goal AUC:MIC targets for the initial 24 hour period.
Strengths of our study included the large sample size, which was sufficiently
powered to determine differences in clinical failure. We built on previous literature by
studying only confirmed cases of MRSA and expanding on the study of pharmacokinetic
outcomes to clinical outcomes of this patient population. Our definition of clinical failure
has been used in other studies of MRSA infection and all components are measured
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objectively, thus not relying on subjective assessments such as clinical resolution.77,78
Anticipating that detecting a difference in an outcome such as ICU length of stay or
vasopressor duration would require several fold additional patients, the outcome of
clinical failure is sensitive to surrogate outcomes such as WBC and temperature changes
over time that may have seen more immediate effects from the loading dose, if present.
The two groups of patients were similar in terms of severity of illness, kidney disease,
and other pre-identified factors that might have predisposed to receipt of a loading dose
or clinical outcome. We also included multiple types of infections commonly afflicting
critically ill patients.
Our study also has noted limitations, including the retrospective, non-randomized,
and single center design. Due to vancomycin dosing practices at the institution, we are
not able to make any inferences about the clinical benefits of loading doses beyond 2,000
mg as only one patient received a > 2,000 mg loading dose. However, a dose cap of 2,000
mg was the most commonly reported dose cap in a prior study of vancomycin dosing
practices among critical care pharmacists suggesting this practice is widespread.75
Relevant to this study, any patient over 100 kg was therefore essentially ineligible to be
categorized as having received a loading dose. Accordingly, whether or not relatively
larger loading doses (up to 3,000 mg as maximally defined in current consensus
guidelines)23 are associated with any clinical benefit remains unknown at this time,
although the lack of dose response noted in the exploratory analysis of loading dose by
quartiles would suggest against this. Our study design also excluded patients weighing ≥
125 kg, thus our results may not be directly applicable to obese patients. The difference
in the initial vancomycin dose between the loading dose and no loading dose cohorts was
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not as drastic as would have been the case if higher loading doses were used in our study.
The loading dose group received an additional 5 mg/kg (or 250-500 mg typically). While
dichotomization of information can have drawbacks, use of a loading dose or not is
typically a dichotomous decision clinically. Additionally, the lack of signal in the quartile
analysis and in the multivariable regression where initial dose was analyzed as a
continuous variable supports the findings that initial dose does not appear to impact
clinical failure. We also did not estimate or measure vancomycin AUC in these groups as
a result of the loading dose, or in subsequent dosing intervals, and thus are unable to
directly compare vancomycin AUC with these clinical outcomes. The known variability
in vancomycin pharmacokinetics in critically ill patients makes it possible that patients in
this study may have not achieved adequate AUC with the loading doses thus explaining
the lack of clinical benefit observed. For example, a significant number of these patients
may have had AKI upon admission or been actively fluid resuscitated at the time of
vancomycin loading dose, which would have increased the Vd and may have influenced
the ability to achieve the target exposure with the vancomycin doses observed in the
study. More patients had respiratory infections than bacteremia, thus if there was a
differential effect of loading doses given the site of infection, we may have been
underpowered to detect it. Finally, although patients appeared to be well-matched based
on identified characteristics, we cannot rule out residual confounding and its effects.
3.5 Conclusion
In critically ill patients with MRSA infection cultured from the blood or
respiratory tract, receipt of a loading dose of vancomycin (≥ 20 mg/kg actual body
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weight) was not associated with any differences in clinical failure, mortality, ICU length
of stay, AKI, or other outcomes when compared to patients not receiving a loading dose.
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Table 3.1 Baseline Demographics
Patient Demographic
Age (years)
Sex (% male)
Culture Site

Loading
Dose (n=103)
54 (38-66)
58 (56.3%)

Blood 34 (33.0%)
Respiratory 55 (53.4%)
Both 14 (13.6%)
Chronic Kidney Disease (%)
8 (7.8%)
End Stage Renal Disease (%)
7 (6.8%)
Service (% medical)
80 (77.7%)
Minimum inhibitory concentration
1 (1-1)
(mcg/ml)a
Long Term Indication for MRSA
12 (11.7%)
Treatmentb
Weight (kg)
68 (61-85)
Initial vancomycin dose (mg)
1500 (12501750)
Initiation vancomycin dose (mg/kg actual 21 (20-22)
body weight)
Number of concurrent nephrotoxins
1 (0-2)
within first 5 days
Vancomycin therapy duration (days)
6 (3-12)
At Time of Vancomycin Initiation
White blood cell count (x103/mm3)
15 (10-21)
Blood urea nitrogen (mg/dl)
23 (15-41)
Serum creatinine (mg/dl)
1.1 (0.7-1.6)
100.4 (98.7Maximum Temperature (°F)
102.0)
Sequential Organ Failure Assessment
8 (5-10)
score
Pitt Bacteremia Score
5 (4-7)
Requirement for vasopressor support (%) 31 (30.1%)
Mechanical ventilation (%)
77 (74.8%)
Lactate (mmol/L)c
1.8 (1.1-3.3)
a
Available for 295 patients
b
Long-term indication defined as ≥ 4 weeks of therapy
c
Available for 366 patients
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No Loading
Dose (n=346)
57 (45-68)
198 (57.2%)
80 (23.2%)
199 (57.7%)
66 (19.1%)
41 (11.9%)
23 (6.7%)
234 (67.6%)
1 (1-1)

pvalue
0.102
0.869
0.099

0.243
0.958
0.051
0.352

25 (7.2%)

0.216

80 (66-97)
1250 (10001500)
16 (15-18)

<0.001
<0.001

1 (1-2)

0.441

6 (3-11)

0.843

13 (9-19)
26 (15-41)
1.0 (0.7-1.7)
100.7 (99.3102.3)
7 (5-10)

0.150
0.625
0.902
0.101

5 (3-7)
105 (30.4%)
254 (73.6%)
1.6 (1.1-3)

0.607
0.961
0.818
0.586

<0.001

0.674

Table 3.2 Study Outcomes
Outcome

Loading
Dose
(n=103)

No Loading
Dose (n=346)

pvalue

Primary Outcome
Clinical failure (%)
77 (74.8%)
252 (72.8%)
0.698
Death within 30 days (%) 20 (19.4%)
77 (22.3%)
-Blood cultures positive ≥ 7 days (%) 12 (11.7%)
16 (4.6%)
-3
3
WBC >12 x10 /mm after 5 days 28 (27.2%)
93 (26.9%)
-36 (10.4%)
-Persistent temperature >100.4° F after 5 8 (7.8%)
days
Substitution/addition of alternative 9 (8.7%)
30 (8.7%)
-treatment
Secondary Outcomes
All-cause mortality in ICU (%)
21 (20.4%)
87 (25.1%)
0.321
Time from vancomycin initiation to ICU
9.4 (4.49.5 (4.9-17.4) 0.880
discharge (days)
16.7)
Acute kidney injury within 5 days of
20 (20.2%)
59 (17.8%)
0.765
vancomycin initiation (%)a
Duration of vasopressor support (days)b
3 (2-5)
3 (2-6)
0.793
Duration of mechanical ventilation (days)c
8.5 (4.3-17)
9 (4-20)
0.632
First vancomycin serum trough
15.6 (11.014.0 (9.5-21.0) 0.056
concentration (mcg/ml)d
24.4)
WBC = white blood cell count
a
Patients with End Stage Renal Disease excluded from assessment
b
Available for the 136 patients requiring vasopressor support at vancomycin initiation
c
Available for the 331 patients requiring mechanical ventilation at vancomycin initiation
d
Available for 361 patients
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Table 3.3 White Blood Cell and Temperature Values Over Time
Value
Loading
No Loading
Dose (n=103) Dose (n=346)
WBC (x103 /mm3)
Day 2
11.8 (8.912.5 (8.9-18.7)
17.3)
Day 3
10.8 (7.911.9 (8.8-17.9)
15.7)
Day 4
11.1 (7.911.3 (7.7-16.5)
15.8)
Day 5
10.7 (7.6-14) 11 (7.4-16.4)
Temperature (°F)
Day 2
Day 3
Day 4
Day 5

100.1 (99.0101.1)
100.0 (98.7101.1)
99.4 (98.6100.4)
99.3 (98.5100.2)
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100.4 (99.1101.4)
99.8 (98.9101.0)
99.6 (98.8100.7)
99.5 (98.7100.5)

pvalue
0.814
0.254
0.936
0.446
0.144
0.680
0.158
0.155

Table 3.4 Primary Outcome Assessed by Quartiles of Initial Dose (mg/kg)
Initial Dose Quartile
No Clinical
Clinical Failure
(mg/kg actual body
Failure (n=120)
(n=329)
a
weight)
1st quartile (7.9-15.1)
29 (25.7%)
84 (74.3%)
nd
2 quartile (15.1-17.2)
34 (30.4%)
78 (69.6%)
3rd quartile (17.2-19.3)
29 (25.9%)
83 (74.1%)
th
4 quartile (19.3-27.6)
28 (25.0%)
84 (75.0%)
a

p=0.794
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Table 3.5 Primary Outcome with Loading Dose Categorized as ≥ 1,750 mg
Outcome
Loading Dose
No Loading Dose
p-value
(n=100)
(n=349)
Clinical Failure (%) 76 (76.0%)
253 (72.5%)
0.485
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Table 3.6 Multivariable Logistic Regression Model for Clinical Failure
Variable
Odds Ratio with
95% Confidence
Interval
First vancomycin dose (mg/kg)
0.98 (0.91-1.06)
Age (years)
1.01 (0.99-1.02)
Sex (male vs. female)
0.73 (0.44-1.21)
Infection Site (compared to blood alone)
Respiratory 0.41 (0.21-0.81)
Concomitant blood and respiratory 0.47 (0.21-1.08)
End stage renal disease
0.17 (0.05-0.56)
Chronic kidney disease
1.06 (0.45-2.46)
ICU service (surgical vs. medical)
1.20 (0.70-2.07)
Day 1 white blood cell count (x103/mm3)
1.08 (1.04-1.12)
Day 1 blood urea nitrogen (mg/dl)
0.98 (0.97-0.99)
Day 1 serum creatinine (mg/dl)
1.35 (1.04-1.76)
0.97 (0.85-1.10)
Day 1 maximum temperature (°F)
Sequential Organ Failure Assessment score
1.23 (1.09-1.37)
Requirement for vasopressor support (%)
0.61 (0.31-1.21)
Mechanical ventilation (%)
0.77 (0.36-1.65)
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pvalue
0.617
0.418
0.226
0.011
0.074
0.003
0.899
0.503
<0.001
0.016
0.023
0.597
<0.001
0.156
0.500

Figure 3.1 Application of Inclusion and Exclusion Criteria
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Figure 3.2 Daily White Blood Cell Count and Temperature Trends
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Figure 3.3 Cumulative Incidence Function for Time to ICU Discharge from Vancomycin
Initiation
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CHAPTER 4 FIRST-DOSE VANCOMYCIN PHARMACOKINETICS

This work has previously been published and permission granted for use in this
dissertation by John Wiley & Sons, Inc:
Flannery AH, Delozier NL, Effoe SA, Wallace KL, Cook AM, Burgess DS. First-Dose
Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target
Attainment in Critically Ill Patients. Pharmacotherapy. 2020 Dec;40(12):1210-1218.
doi: 10.1002/phar.2486.
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4.1 Introduction
Revised consensus guidelines for therapeutic drug monitoring (TDM) of
vancomycin recommend a shift from trough-based monitoring to area-under-the-curve
(AUC) monitoring, with a daily goal (assuming a minimum inhibitory concentration
(MIC) of 1 mg/L) of 400-600 mg·h/L.23 Failure to obtain sufficient AUC/MIC target
attainment early in therapy (days 1 and 2) has been associated with treatment failure in
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis.73,91 On
the other hand, AUC values greater than 600-650 mg·h/L are associated with acute
kidney injury (AKI).37,92 Critically ill patients with infection are already susceptible to
AKI and often show altered pharmacokinetic changes that can markedly impact
vancomycin’s volume of distribution (Vd) and clearance (CL).93 Thus, approaches to
optimize vancomycin AUC target attainment early in therapy for critically ill patients
with confirmed or suspected MRSA infection are needed.
As an early adopter of AUC-guided vancomycin dosing, our center has several
years of experience with AUC monitoring of vancomycin in a wide variety of patient
populations.94 We developed a protocol using serum vancomycin concentrations obtained
following the first dose of vancomycin to calculate patient-specific pharmacokinetic
parameters used for further dosing as one approach to target precision dosing of
vancomycin in high-risk patients, including the critically ill. Alternatively, empiric
dosing based on population pharmacokinetic estimates was also available as a method to
develop initial vancomycin regimens targeted at AUC values. The use of first-dose
kinetics to guide dosing and the subsequent impact on vancomycin trough attainment has
demonstrated mixed results in prior studies.42,43 The availability of both dosing
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approaches allowed a unique opportunity to compare dosing strategies of vancomycin on
AUC target attainment in critically ill adults.
We sought to test a personalized dosing strategy, using two concentrations
following the initial dose of vancomycin and employing first-dose pharmacokinetic
calculations to guide subsequent dosing, versus dosing with population pharmacokinetic
estimates on the outcome of vancomycin AUC target attainment assessed at steady state
(SS) in critically ill patients receiving vancomycin.
4.2 Methods
4.2.1 Study Design
The University of Kentucky Chandler Medical Center is an 865-bed tertiary care
referral center for the state and surrounding region. For inpatients, all scheduled
vancomycin therapy is dosed per pharmacist protocol approved by the Pharmacy and
Therapeutics Committee. Pharmacists may alter vancomycin dosages, order vancomycin
levels, and order laboratory tests for monitoring such as a basic metabolic panel for
serum creatinine. In September of 2017, in anticipation of vancomycin TDM guideline
changes, the monitoring of vancomycin was changed from trough-based to AUC as
previously described.94
In a retrospective cohort design, all patients admitted to the medical intensive care
unit (MICU) from September 2017 to June 2019 with at least two vancomycin serum
concentrations ordered to calculate AUC at SS and receiving > 1 dose of intravenous
vancomycin were assessed for inclusion in the study. Patients were excluded if serum
concentrations were obtained following the first dose but no SS levels (therapy was
discontinued before SS concentrations obtained), if receiving intermittent vancomycin
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dosing due to AKI or the receipt of renal replacement therapy, if they received
vancomycin at an outside hospital prior to transfer (as first-dose vancomycin
concentrations would not have been able to be obtained), or if the vancomycin
concentrations were drawn incorrectly (i.e. drawn from non-flushed catheter) or
laboratory error was suspected by the assessing pharmacist as determined by documented
records.
This resulted in a cohort of critically ill patients that received vancomycin with at
least two SS levels obtained for AUC calculation. From this cohort, two groups were
identified: those patients in whom vancomycin concentrations were obtained following
the first dose to guide subsequent dosing (first-dose kinetics) and those patients dosed
based on population estimates (empiric dosing). Accordingly, the first-dose kinetics
group had four vancomycin concentrations drawn (two for first-dose pharmacokinetic
calculation and two at SS for AUC calculation) and the empiric dosing group had two
concentrations assessed (at SS for AUC calculation). The primary outcome was goal
AUC target attainment (defined as 400-600 mg·h/L) at SS. Secondary outcomes included
AKI between the first-dose kinetics and empiric dosing groups (assessed starting at the
time SS levels were drawn and up to 48 hours following SS levels using the serum
creatinine component of the Kidney Disease Improving Global Outcomes [KDIGO]
criteria79) and a comparison of pharmacokinetic parameters (elimination rate constant
(ke), Vd, CL,) between the time of first dose and SS in the first-dose kinetics group.
Pharmacokinetic parameters and creatinine clearance were also compared between the
first-dose kinetics group and empiric dosing group at steady state to ensure
comparability. Requisite data were collected on serum vancomycin concentrations,
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vancomycin doses, infusion times, intervals, and time stamps necessary to confirm
calculated AUC. Demographic data collected include patient age, sex, weight, height,
serum creatinine, serum blood urea nitrogen, Sequential Organ Failure Assessment
(SOFA) score80, and receipt of concurrent nephrotoxins from initiation of vancomycin up
to 48 hours following SS (defined as angiotensin converting enzyme inhibitors, acyclovir
(intravenous), aminoglycosides, amphotericin B, angiotensin receptor blockers, colistin,
foscarnet, nonsteroidal anti-inflammatory drugs, polymyxin B,
sulfamethoxazole/trimethoprim, tacrolimus (intravenous), and piperacillin /tazobactam).
Creatinine clearance (CrCl) was estimated with Cockcroft-Gault95 or Salazar-Corcoran96
if greater than 125% of ideal body weight. The electronic medical record was manually
reviewed to obtain the necessary data and confirm accuracy of all calculations. The study
was approved by the Institutional Review Board at the University of Kentucky.
4.2.2 Vancomycin Dosing Protocol
During the study period, two options existed for calculation of empiric
vancomycin dosing for patients with stable renal function. One option allowed for
assessing two serum vancomycin concentrations following the first dose and using firstdose pharmacokinetics to develop a personalized dosing regimen based on the patient’s
established pharmacokinetic parameters. This approach was primarily used in the MICU
as opposed to other units in the hospital based on pharmacist preference. Alternatively,
population estimates for Vd and ke could be used to develop a regimen anticipated to
produce a daily AUC of 400-600 mg·h/L (Appendix 2). A loading dose of 25 mg/kg is
recommended for all patients with serious infections in the institutional protocol
regardless of the initial dosing strategy selected. An AUC of 500 mg·h/L was the
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recommended target when designing a regimen, assuming as consensus guidelines
recommend, an MIC of 1 mg/L.23 The decision to order vancomycin levels following the
first dose to guide subsequent dosing or to use population estimates to inform an initial
maintenance dose is at the discretion of the pharmacist ordering the initial dosing of
vancomycin. Two vancomycin concentrations at SS, either peak/trough or two random
levels following the SS dose, are included in the dosing protocol to calculate the AUC.
SS levels are recommended around the 4th dose of vancomycin, but pharmacists can use
their judgement to assess earlier or later based on clinical characteristics or to avoid
vancomycin level assessment during sleeping hours. Using these concentrations, we used
first-order pharmacokinetic equations as recommended by consensus guidelines to
calculate pharmacokinetic parameters and AUC values (Appendix 2).23,97,98
4.2.3 Statistical Analysis
Patient demographic data are reported as proportions or means/medians, as
appropriate per the distribution. AUC target attainment and nephrotoxicity between
groups were evaluated using the Chi-Square test. For the analysis of AUC target
attainment, logistic regression was used to adjust for any significant differences in
relevant baseline characteristics between the two cohorts that may have served as
confounders as assessed by study investigators. Continuous data between the first-dose
kinetics and empiric dosing group were compared using the independent samples t-test or
Wilcoxon rank-sum test depending on the distribution. When comparing CrCl or
pharmacokinetic parameters within the same group from baseline to SS, the Wilcoxon
signed-rank test was used. Data were analyzed using Stata (StataCorp. 2019. Stata
Statistical Software: Release 16. College Station, TX: StataCorp LLC).
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4.3 Results
Of 160 patients admitted to the MICU meeting potential inclusion criteria during
the study period, 94 were excluded, with the most common reasons being AKI (n=64) or
therapy not continued long enough for SS level evaluation (n=20) (Figure 4.1). Sixty-six
patients met the full inclusion criteria: 29 patients with first-dose kinetics and 37 patients
with empiric vancomycin dosing. All patients received intermittent intravenous infusions
of vancomycin.
Baseline characteristics were well-balanced between the two cohorts (Table 4.1),
with the only significant differences being that patients in the first-dose kinetics group
received a slightly higher initial dose of vancomycin compared to the empiric dosing
group (2043 ± 449 mg vs. 1568 ± 499 mg; p<0.001) and the time from the first dose of
vancomycin to the first steady state concentration assessment was slightly longer in the
first-dose kinetics group (60 (50-80) hours vs. 47 (37-67) hours; p=0.018) compared to
the empiric dosing group. Importantly, patients were well-matched on age, baseline renal
function (including CrCl), severity of illness, and receipt of concurrent nephrotoxins.
The primary outcome, target AUC target attainment at SS (400-600 mg·h/L), was
achieved in 58.6% of first-dose kinetics patients compared to 32.4% with empiric dosing
(p=0.033). For those not meeting the desired AUC goal, patients in the empiric dosing
group were more likely to be subtherapeutic (40.5%) compared to the first-dose kinetics
group (3.5%). First-dose kinetics patients, when not achieving AUC target attainment,
were more likely to be supratherapeutic compared to the empiric dosing group (37.9% vs.
27.0%). Correspondingly, the median AUC, estimated peak, and trough concentrations
were greater in the first-dose kinetics group compared to the empiric dosing cohort. The
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minimum and maximum AUC values were numerically more extreme, and the overall
variability in AUC at SS was greater (coefficient of variation 40.7% vs. 26.1%), in the
empiric dosing group compared to the first-dose kinetics group (Figure 4.2).
Pharmacokinetic parameters and CrCl at steady state were similar between the two
groups (Table 4.2). There was no difference between groups in AKI assessed from SS up
to 48 hours following collection of vancomycin concentrations at SS.
In simple logistic regression, the use of first-dose kinetics vs. empiric dosing was
associated with a 2.95 greater odds of AUC target attainment at SS (OR 2.95 95% CI
1.08-8.10). When adjusted for initial vancomycin dose and time to steady state
concentration assessment (neither of which were significantly associated with AUC target
attainment in the model), similar results were obtained with a 3.33 greater odds for SS
AUC target attainment with first-dose kinetics (OR 3.33 95% CI 1.03-10.72) compared to
empiric dosing.
The estimated CrCl increased in both groups from the time of the first dose of
vancomycin to SS: from 107 (66-143) to 110 (78-156) mL/min in the first-dose group
(p=0.094 via pair-wise comparison) and from 109 (73-151) to 141 (98-179) mL/min in
the empiric dosing group (p<0.001 via pair-wise comparison). In the group of patients
with first-dose kinetics, calculated pharmacokinetic parameters were similar between the
time of first-dose and SS, with the only exception calculated CL which was greater at the
time of first-dose than at SS (Table 4.3).
4.4 Discussion
The AUC/MIC ratio is recommended in consensus guidelines as the
pharmacokinetic/pharmacodynamic monitoring parameter of choice for vancomycin
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when treating MRSA infections.23 This parameter, related to both efficacy and safety of
vancomycin, has particular relevance to critically ill patients who are at high risk of
complications from MRSA as well as at high risk of AKI with multiple nephrotoxic risk
factors. We showed that patients dosed using a personalized dosing approach with firstdose pharmacokinetics to drive subsequent dosing experienced greater AUC target
attainment at SS versus empiric dosing. Although the study was observational in design,
the two groups were well-balanced except for two parameters that differed by clinically
questionable magnitudes: initial dose of vancomycin differed by approximately 500 mg
and time from vancomycin initiation to SS concentration assessment differed by
approximately 12 hours. We suspect the longer time to SS concentration evaluation may
have been due to pharmacist confidence in the dosing regimen selected given the firstdose pharmacokinetic approach and willingness to wait longer to assess as compared to
empiric dosing. Even when adjusted for these differences as potential confounders, the
use of first-dose kinetics was consistently associated with a greater likelihood of AUC
target attainment at SS. As early and accurate AUC target attainment is increasingly
recognized as important in MRSA infections, this approach offers one way to increase the
likelihood of AUC target attainment as compared to empiric dosing.
Casapao and colleagues, in a retrospective study of patients with MRSA infective
endocarditis, concluded that failure to obtain a day 1 vancomycin AUC/MIC of at least
600 was associated with an increased risk of treatment failure, defined as persistent
bacteremia (≥ 7 days) or 30-day attributable mortality.91 Lodise and colleagues similarly
found that day 1 and 2 vancomycin AUC/MIC thresholds (values dependent on MIC
methodology) were associated with fewer treatment failures, defined as 30-day mortality,
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bacteremia ≥ 7 days, or recurrence.73 The association of vancomycin AUC with AKI is
relevant in the early therapy window as well. In a recent meta-analysis, a vancomycin
AUC < 650 mg·h/L on day 1 or 2 was associated with less AKI.37 Thus, there is a critical
need, particularly in an at-risk population such as critically ill patients, for early and
accurate attainment of vancomycin AUC to optimize the chance of clinical efficacy and
minimize the risk of AKI.
The approach of using patient-specific pharmacokinetic parameters obtained from
two serum concentrations following the first dose in designing regimens for vancomycin
has produced mixed results.42,43 In critically ill patients, Truong and colleagues
demonstrated that using patient-specific pharmacokinetic parameters derived from two
serum concentrations following the first dose of vancomycin resulted in greater goal
trough concentrations compared to those patients dosed without first-dose
pharmacokinetic monitoring.43 Conversely, in pediatric patients, first-dose monitoring of
vancomycin did not significantly shorten the time to achieve target serum drug
concentrations.42 These prior studies have used trough levels as target attainment, which
limits application to some extent in the era of vancomycin AUC-guided dosing.
Therefore, we sought to study AUC target attainment at SS in critically ill patients dosed
with first-dose kinetics versus empiric dosing.
Similar to Truong et al,43 we observed greater target attainment in the first-dose
group compared to empiric dosing. Neither study demonstrated a reduction in the
incidence of AKI with this approach, although both studies were likely underpowered for
the outcome of AKI. Our pharmacokinetic parameters calculated and their variability are
similar to other published parameters from vancomycin in critically ill adults.74
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Pharmacokinetic parameters in this patient population were generally similar between the
start of vancomycin and SS, further bolstering the validity of using first-dose
pharmacokinetic calculations in critically ill patients with relatively stable renal function.
This approach was shown to be beneficial for vancomycin, but may have utility with
other antibiotics as well such as beta-lactams99 given the time-critical nature of
pharmacokinetic/pharmacodynamic target attainment in critically ill patients.
Additionally, this approach may be suitable for high risk patients admitted to non-ICU
services. It was recently demonstrated that vancomycin AUC target attainment in patients
with MRSA complicated skin and soft tissue infections was associated with timely
clinical success and a trend toward a shorter hospital length of stay.100 Thus, our results
could be extrapolated outside of the critically ill patient population to a broader cohort of
hospitalized patients with MRSA infection that would benefit from early and precise
AUC target attainment.
While this approach demonstrated success in producing goal SS AUC target
attainment with a number needed to treat of 4, there are challenges to using this approach
that deserve mention. First, if this approach was applied universally, a number of patients
would receive therapeutic drug monitoring after the first dose of vancomycin that may go
on to receive less than 48 hours of vancomycin therapy. Assuming a patient continues to
receive vancomycin until concentrations are assessed at SS, this approach results in 4
vancomycin serum concentrations within a period of days. These costs are combined with
the labor costs of pharmacokinetic evaluation, with the realization that overnight
evaluation of levels may be required depending on the timing of vancomycin initiation.
The pharmacist resources necessary for the potential increase in the need for assessment
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of vancomycin concentrations may not exist equally at all hospitals. The use of Bayesian
dose optimization tools may help limit the number of required samples if using this
approach. The use of first-dose kinetics also requires a presumption of stable renal
function at the time of first-dose kinetics and anticipation that renal function will be
similar at SS, which may be difficult to predict. Although CrCl increased numerically in
both the first-dose kinetics and empiric dosing groups, it was relatively stable from a
clinical standpoint from baseline to SS. As such, patients targeted for this approach
would need to have presumed stable renal function at the time of vancomycin initiation
and anticipated to maintain stable renal function by the time of SS evaluation.
Augmented renal clearance has also been noted in sepsis and critically ill patients, which
may influence first-dose pharmacokinetic calculations if present and risk over-estimating
clearance.101,102 As noted, a significant number of patients were excluded due to active
AKI, which limits the approach of first-dose kinetics. While empiric dosing was more
likely to provide subtherapeutic AUC exposure compared to first-dose kinetics, Figure
4.2 shows a cluster of AUC exposures in the empiric group between 350-400 mg·h/L,
which for empiric therapy with no MRSA isolated may be clinically appropriate.
However, for severe, confirmed MRSA infection, an AUC of 400-600 mg·h/L would be
desired. A high-risk population, either at risk of MRSA isolation or with multiple AKI
risk factors, might be identified to benefit most from the patient-specific dosing afforded
from obtaining vancomycin serum concentrations following the first dose. This approach
is particularly feasible as rapid diagnostics and clinical prediction rules for MRSA
continue to be refined. Despite the improved AUC target attainment at SS compared to
empiric dosing, the target attainment in the first-dose kinetics group was still limited to
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58.6%, which identifies the need for greater precision dosing mechanisms for
vancomycin in critically ill patients, potentially including use of continuous infusion.70
Over one-third of patients in the first-dose kinetics group had AUC values above goal at
SS, which may be due to acute changes in pharmacokinetics in critically ill patients. This
is another area where application of Bayesian technology may assist with fluctuating
renal function that may not meet traditional AKI criteria.
Our study is not without limitations worthy of discussion. First, this study’s
sample size was known to be small in the design phase due to the finite population of
patients with first-dose kinetics and steady state levels, thus the study was underpowered
for AKI detection. Clinical efficacy outcomes were not assessed as it was recognized
only a fraction of these patients would have true MRSA infection. Second, although the
groups were generally similar at baseline, the initial loading dose was slightly higher in
the first-dose kinetics group and more time had passed in the first-dose group when SS
concentrations were assessed. Prior studies report mixed results on the impact of initial
loading dose on target attainment at steady state,87,103 and the difference between groups
was less than 500 mg, which may not be clinically relevant 2-3 days later when SS
concentrations are assessed. Additionally, the effect estimate of using the first-dose
kinetics strategy was similar when adjusting for initial dose and time to SS concentrations
in the logistic regression model. The lower initial dose could indicate non-compliance
with institutional dosing protocols in the empiric dosing group. The appropriateness of
initial dosing in the empiric group was not assessed in our group, and we acknowledge
that clinical judgement may influence a pharmacist’s dosing recommendations at the
expense of protocol non-compliance.75 Third, the CrCl increased numerically in both
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groups between baseline and SS, but was greater in the empiric dosing group, which may
partially explain the greater subtherapeutic AUC values in the empiric dosing group vs.
the first-dose kinetics group. There are also are a number of inherent assumptions in
using these pharmacokinetic equations, such as the assumption that serum concentrations
are obtained at least one half-life apart as well as the fact that two compartment
elimination is sometimes possible to observe, particularly if the initial post-dose level is
drawn too soon. These assumptions may have contributed to the AUC target attainment
in the first-dose kinetics group not being higher. Finally, unmeasured confounders could
have biased the results if systemic differences existed between first-dose kinetics and
empiric dosing groups aside from pharmacist preference at the time of initial dosing.
4.5 Conclusion
A dosing strategy using two vancomycin serum concentrations following the first
dose and calculating personalized pharmacokinetic parameters to guide subsequent
dosing is associated with greater AUC target attainment at SS compared to empiric
dosing of vancomycin in critically ill adults. Future applications of this strategy to other
antibiotics in the ICU, non-ICU patient populations, identification of patients most likely
to benefit, and comparison to Bayesian approaches using concentrations after the first
dose are future areas for research.
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Table 4.1 Patient Demographics
Baseline Characteristics

First Dose Kinetics
Empiric Dosing
p-value
(n=29)
(n=37)
Age (years)
54.0 ± 17.2
46.6 ± 14.3
0.060
Sex (% male)
15 (51.7%)
20 (54.1%)
0.851
Weight (kg)
84.3 (72.5-106.8)
80.0 (60.4-94.2)
0.165
Initial dose (mg)
2043 ± 449
1568 ± 499
<0.001
Expressed as mg/kg ABW 24 (22-25)
19 (16-23)
<0.001
Serum creatinine at
0.89 ± 0.32
0.91 ± 0.37
0.813
vancomycin initiation (mg/dL)
Blood urea nitrogen at
18 (13-30)
19 (13-25)
0.660
vancomycin initiation (mg/dL)
Estimated creatinine clearancea 107 (66-143)
109 (73-151)
0.841
at vancomycin initiation
(mL/min)
SOFA score
7.4 ± 3.0
7.3 ± 2.7
0.884
Total daily maintenance dose
2629 ± 820
2426 ± 1027
0.387
(mg)
Receipt of concurrent
23 (79.3%)
24 (64.9%)
0.198
nephrotoxins (%)
Time from first dose to SS
59.6 (50.4-79.8)
47.4 (36.5-67.4)
0.018
concentration assessment
(hours)
a
Calculated using Cockcroft-Gault or Salazar-Corcoran (if weight greater than 125% of ideal
body weight). ABW=actual body weight; SOFA=Sequential Organ Failure Assessment;
SS=steady state
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Table 4.2 Study Outcomes
Outcome

Achievement of target AUC
at steady state (%)
Below 400 mg·h/L
Above 600 mg·h/L
AUC at steady state
(mg·h/L)
Acute kidney injury (%)
Estimated Trough
Concentration (mg/L)
Estimated Peak
Concentration (mg/L)
ke (hr-1)
Half-life (hr)
Volume of distribution (L)

First-Dose Kinetics
(n=29)
17 (58.6%)

Empiric Dosing
(n=37)
12 (32.4%)

p-value

1 (3.5%)
11 (37.9%)
575 (491-722)

15 (40.5%)
10 (27.0%)
438 (379-650)

----0.006

4 (13.8%)
16.4 (12.0-18.7)

4 (10.8%)
11.5 (6.8-17.2)

0.713
0.020

36.4 (31.1-41.4)

32.1 (23.6-37.8)

0.049

0.078 (0.047-0.121)
8.9 (5.7-14.7)
54.6 (42.2-86.5)

0.070 (0.054-0.126)
9.9 (5.5-12.8)
55.6 (39.7-87.8)

0.647
0.647
0.892

4.6 (3.1-6.5)
141 (98-179)

0.811
0.072

Clearance (L/hr)
4.8 (3.4-5.5)
Creatinine Clearance
110 (78-156)
(mL/min)
AUC=area-under-the-curve; ke=elimination rate constant
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0.033

Table 4.3 Pharmacokinetic Parameter Comparison Between First-Dose and Steady State
in the First-Dose Kinetics Group
Parameter
ke (hr-1)
Volume of distribution (L)
Volume of distribution
(L/kg)
Clearance (L/hr)
ke=elimination rate constant

Time of first dose
(n=29)
0.084 (0.060-0.115)

p-value

64.0 (45.0-72.9)
0.70 (0.51-0.81)

Steady state
(n=29)
0.078 (0.0470.121)
54.6 (42.2-86.5)
0.58 (0.45-0.99)

5.0 (4.0-6.5)

4.8 (3.4-5.5)

0.012
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0.122
0.804
0.689

Figure 4.1 Flow Diagram for Inclusion and Exclusion
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Figure 4.2 AUC Variability and Target Attainment by Dosing Strategy
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CHAPTER 5 VANCOMYCIN CONTINUOUS VERSUS INTERMITTENT
INFUSION: SYSTEMATIC REVIEW AND META-ANALYSIS

This work has previously been published and permission granted for use in this
dissertation by Wolters Kluwer Health, Inc.:
Flannery AH, Bissell BD, Bastin MT, Morris PE, Neyra JA. Continuous Versus
Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill
Adults: A Systematic Review and Meta-Analysis. Crit Care Med. 2020 Jun;48(6):912918. doi: 10.1097/CCM.0000000000004326.
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5.1 Introduction
Vancomycin is one of the most commonly prescribed antibiotics in the inpatient
setting, particularly in the intensive care unit (ICU), for empiric coverage of methicillinresistant Staphylococcus aureus (MRSA). Despite extensive clinical experience, a
number of questions remain regarding its optimal use, including: pharmacokinetic
(PK)/pharmacodynamic (PD) targets translated from experimental models which inform
clinicians of optimal drug levels to maximize efficacy of the drug, ideal methods of
administration, and techniques to minimize toxicities.62 The most clinically relevant
adverse effect from vancomycin remains acute kidney injury (AKI), and the clinician
must balance achieving relevant PK/PD targets with the risk of AKI. Particularly in the
vulnerable critically ill patient facing many other kidney insults, the risk of vancomycinassociated AKI may be even higher in this patient population.104 AKI rates with
vancomycin are reportedly as high as 35% when prescribed with other antibiotics, as is
commonly done in the ICU.38 Furthermore, AKI in hospitalized patients is associated
with significant increases in mortality, length of stay, and health care costs 105.
Prior work attempting to summarize the effect of continuous versus intermittent
vancomycin infusion on AKI in meta-analyses is limited by three main factors: 1.)
including a broad mix of patient presentations vastly different from one another
(outpatient antimicrobial therapy and ICU patients in the same evaluation) has
subsequently lead to conflicting conclusions among meta-analyses, 2.) meta-analytic
techniques using raw numbers from observational research rather than odds ratios which
more accurately reflect adjustment for confounding factors in the individual studies (if
performed), and finally, 3.) prior reports are not inclusive of all available literature given
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an increasing trend of publications regarding continuous infusion vancomycin.56,57,106 We
therefore conducted a systematic review and meta-analysis of continuous versus
intermittent infusion vancomycin and the associated risk of AKI in critically ill adults.
5.2 Materials and Methods
5.2.1 Search Strategy and Study Selection
With the assistance of an experienced medical librarian, we conducted a
systematic search using PubMed/MEDLINE, CINAHL, Web of Science, International
Pharmaceutical Abstracts, and Google Scholar from inception to June 2017. References
of relevant articles and personal files were also included. A combination of search terms
was used, including variants of the following: critical care, intensive care, vancomycin,
continuous, and intermittent. We included randomized clinical trials or cohort studies
(retrospective or prospective, including quasi-experimental) comparing AKI or
nephrotoxicity between continuous and intermittent infusion of vancomycin in adult
patients. We only included ICU patients as clearly identified in the study methods. We
excluded studies comparing the two regimens in patients on continuous renal replacement
therapy given the outcome of interest (AKI) had already occurred. Only peer-reviewed
publications were included; conference proceedings were not considered for inclusion.
Two authors independently assessed articles for inclusion, with discrepancies resolved
via discussion among authors or with the assistance of a third author, if needed. The
search was updated in September of 2019. The protocol is registered on PROSPERO
2017:CRD42017053746 and reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) recommendations.107
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5.2.2 Data Extraction, Risk of Bias, and Outcomes
Data elements from included studies were extracted and confirmed by two authors
using a standardized table. Variables included: year of study, study design, ICU type,
infection type (pathogen and source), definition of AKI/nephrotoxicity, pharmacokinetic
goal ranges for both infusion strategies, use of a loading dose, dosing regimen, age,
weight, gender, baseline serum creatinine, mean/median daily dose and duration, and
frequency of concomitant nephrotoxins.
Risk of bias was assessed with the Cochrane Risk of Bias Assessment Tool for
randomized clinical trials and with the Newcastle-Ottawa scale for observational
studies.108,109 Two authors independently assessed risk of bias, with discrepancies
resolved via discussion among investigators or with the assistance of a third author, if
needed.
The primary outcome was AKI/nephrotoxicity, as defined according to each
study’s definitions. Mortality was assessed as a secondary outcome, as was % target
attainment for the pharmacokinetic goal (typically a trough level for intermittent infusion
and plateau level for continuous infusion) set by the dosing protocol in the study. Data
were extracted for these binary outcomes as both counts as well as odds ratio (OR) with
95% confidence intervals (CI). If an adjusted analysis was performed, the OR and 95%
CI were extracted from the adjusted analysis reported for a study. If the data were
presented as counts, the OR and 95% CI was manually calculated.
5.2.3 Data Synthesis and Analysis
Meta-analyses were performed using RevMan v5.3 (The Cochrane Collaboration,
Oxford, UK) and R (R Foundation for Statistical Computing, Vienna, Austria) using the
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meta package.110 The risk of publication bias was assessed with the use of a funnel plot
and Harbord test.111 The generic inverse variance method was used to pool ORs from
each included study for AKI and mortality. The Mantel-Haenszel method was used for
proportions with count data for percentage target attainment for the pharmacokinetic
secondary outcome. Heterogeneity was assessed with the I2 statistic. Given the
anticipated heterogeneity in study designs and definitions, a random effects model was
selected as the most conservative approach.
5.3 Results
5.3.1 Search Results and Study Characteristics
Following removal of duplicates from the search strategy, 311 unique citations were
screened for inclusion. A large portion of these (n=121) were excluded for only
evaluating one method of infusion strategy. Of the 29 studies remaining following
application of the exclusion criteria, 6 studies did not meet criteria to be classified as
studying critically ill patients. Of the 23 studies remaining, 11 met criteria for inclusion in
the analysis of the primary outcome. Complete search results and identification of
included studies are shown in Figure 5.1.
We identified 11 total studies published over a 23 year period, which evaluated
2,123 patients for the primary outcome of AKI.54,55,71,112-119 Study characteristics,
demographics, and definitions are provided in Table 5.1. Two studies were randomized
trials, 3 were prospective observational, and 6 were retrospective cohort studies.
Collectively, the studies investigated a wide range of ICU populations including medical,
surgical, trauma, neurologic, cardiac, and burns. While some studies focused on a
particular type of infection, the majority of studies evaluated a range of common
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infections in the ICU setting. While the definitions of nephrotoxicity differed across
study groups, all but 3 studies included an increase of serum creatinine by 50% from
baseline as at least part of the definition.54,55,71,112-119 Dosing targets for single
concentrations (continuous group) and troughs (intermittent) varied, but the most
common recurring targets were 20-25 mg/L for continuous infusion and a trough of 1520 mg/L for intermittent dosing. Loading doses were more commonly noted in the
continuous infusion group. Initial dosing regimens varied across studies as well, with 15
mg/kg q8-12h being the most common in the intermittent group and 30 mg/kg/day the
most common in the continuous group. Duration of treatment ranged from approximately
1-2 weeks in many of the studies. Patients were predominately male and, when reported,
were commonly exposed to different nephrotoxic medications.
5.3.2 Risk of Bias
A complete table with the risk of bias assessments is included in Table 5.2. The
randomized clinical trials both had at least two areas at high risk of bias,54,55 notably with
regard to blinding of participants/personnel and incomplete outcome data. Six of the
observational studies were classified as low risk of bias (scored of 7-9), 3 studies as high
risk of bias (score of 4-6), and none as very high risk of bias (score of 0-3).71,112-120 A
funnel plot (Figure 5.2) suggests minimal publication bias. This was confirmed with the
Harbord test (p=0.66).111
5.3.3 Acute Kidney Injury
The incidence and OR for study outcomes are displayed in Table 5.3. The pooled OR
suggests an association between continuous infusion of vancomycin and a reduction in
AKI when compared to intermittent infusion of vancomycin (OR 0.47; 95% CI 0.3481

0.65) and is shown in Figure 5.3. Heterogeneity was fairly low with I2 of 15%. In
sensitivity analysis, the observational studies (n=9) contribute heavily to the overall
findings (OR 0.44; 95% CI 0.31-0.63) compared to the randomized controlled trials (n=2)
(OR 0.72; 95% CI 0.30-1.73) (Figure 5.4). A sensitivity analysis was also performed to
assess the risk of bias in contributing to the findings. For those studies deemed to be low
risk of bias (randomized trials and those observational studies with a Newcastle-Ottawa
score ≥ 7) (n=8), the OR for AKI with continuous infusion was less pronounced (OR
0.52; 95% CI 0.33-0.82) in comparison to those studies deemed high risk of bias (n=3)
(OR 0.37; 95% CI 0.22-0.61), but both analyses were statistically significant favoring
continuous infusion to attenuate the risk of AKI (Figure 5.5). Additional sensitivity
analysis assessing the impact of AKI/nephrotoxicity criteria comparing more sensitive
definitions such as 50% increase in serum creatinine from baseline with more severe
definitions such as need for renal replacement therapy yielded similar point estimates
(Figure 5.6). In order to assess the impact of target trough concentrations in the
intermittent arm and evaluate if higher troughs were possibly contributing to elevated
area-under-the-curve (AUC) drug exposure, a sensitivity analysis was performed based
on the target trough concentration: higher (15-20 mg/L) or lower (5-15 mg/L) (Figure
5.7). Point estimates were again similar and statistically significant in both groups.
Finally, in order to assess the impact of time and practice changes in regard to
vancomycin dosing targets, a cumulative meta-analysis was conducted (Figure 5.8). As
the pooled estimate was updated with each additional study, particularly during the time
period 2001-2013, the beneficial effects of continuous infusion evolved and stabilized at
the current point estimate.
82

5.3.4 Mortality
Eight of the 11 included studies evaluated mortality, either as ICU or overall hospital
mortality. There was no association between the infusion strategy of vancomycin and
mortality in critically ill patients (OR 1.04; 95% CI 0.80-1.35) (Figure 5.9). Low
heterogeneity was present (I2 0%).
5.3.5 Pharmacokinetic Target Attainment
Five of the included studies assessed in a dichotomous fashion the frequency with which
the infusion strategy resulted in the goal pharmacokinetic target attainment for the
protocol. These targets were a given concentration range for troughs for intermittent
infusion and a single level range for continuous infusions. As compared to intermittent
infusion, continuous infusion was associated with a 2.63 greater odds of pharmacokinetic
target attainment (OR 2.63; 95% CI 1.52-4.57) (Figure 5.10). Moderate heterogeneity
was present (I2 45%).
5.4 Discussion
This study represents the most focused systematic review and meta-analysis investigating
the risk of AKI when comparing continuous with intermittent infusion of vancomycin in
critically ill adults. The pooled estimates indicate the use of continuous infusion as
compared to intermittent infusion of vancomycin is associated with an approximate 50%
reduction in the odds of AKI. Given the ubiquity of vancomycin use in critically ill
patients and the substantial morbidity and costs associated with AKI, the method of
administration may have important effects on the drug safety profile without altering
efficacy. Indeed, we found no difference in our secondary outcome of mortality between
the two infusion strategies.
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Our study has many strengths, including the robust search strategy and focused
patient selection that allowed us to examine the effects of infusion strategy in critically ill
adults. Additionally, our meta-analytic techniques allowed us to pool adjusted Ors rather
than raw, unadjusted numbers from prior reports. This is the most likely explanation why
our study suggested a beneficial effect of continuous infusion vancomycin while a prior
meta-analysis did not, as this method of data extraction and analysis is particularly
important for a large cohort study under consideration that reported different effects on
AKI in unadjusted and adjusted analysis.57,71
As recently demonstrated in an animal model, the AUC and maximum
concentration (Cmax) of vancomycin during the dosing interval are most associated with
injury biomarkers of AKI, specifically kidney injury molecule-1 (KIM-1).121 These data
offer a potential mechanism to suggest a scientific rationale for the findings of our metaanalysis: by avoiding high peak concentrations of vancomycin through delivery via a
continuous infusion rather than intermittent dosing, the risk of vancomycin-associated
AKI may be minimized. These markers of kidney injury were found in animals despite
only 24 hours of exposure to vancomycin, thus the potential benefits of continuous
infusion may be relevant to not only definitive MRSA therapy, but empiric therapy as
well. In addition to the potential safety benefit, continuous infusion of vancomycin may
be advantageous compared to intermittent infusion for other reasons. We found
continuous infusion was associated with much greater pharmacokinetic target attainment
(as dictated by the study’s dosing protocol) when compared to intermittent infusion.
Given the anticipated guideline change to recommend AUC (as opposed to trough)
monitoring for vancomycin,23 continuous infusion has many advantages. Vancomycin
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monitoring costs may be minimized with continuous infusion (1 level required for
evaluation) compared to intermittent infusion (2 levels required for evaluation).
Additionally, dosing adjustments require far fewer assumptions and calculations and are
vastly simplified with the continuous infusion approach. Continuous infusion may offer
superior AUC/MIC target attainment over the dosing interval with less variability and
thus optimize the delivery of vancomycin.122 Practically, a loading dose of 15-25 mg/kg
is often recommended, followed by the maintenance dose infused over 24 hours.
Following infusion of the drug for 24-48 hours and assuming relatively stable renal
function, a level can be drawn and multiplied by 24 to obtain the AUC exposure.
Despite these possible advantages, certain barriers may limit the adoption of
continuous infusion of vancomycin in all critical care settings. In an experiment
involving human umbilical vein endothelial cells, vancomycin given continuously was
noted to cause more endothelial cell toxicity compared to intermittent infusion.123 The
Infusion Nurses Society identifies vancomycin as an intermediate-risk vesicant based on
conflicting data.124 Given this, some institutions will choose to limit continuous infusion
to central line administration only while others have successfully reported peripheral
administration at concentrations of 6 mg/mL or less.113 Drug compatibility issues may
also arise depending on availability of intravenous access when continuously infusing
vancomycin.
This systematic review and meta-analysis is not without limitations. First, the
majority of studies included in this systematic review and meta-analysis are
observational, which limits their validity in comparison to prospective randomized trials.
The two randomized trials we did include have possible biases as well as limited sample
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size (n=174 combined). However, the sensitivity analysis including only low risk of bias
studies revealed a similar point estimate to the primary analysis, suggesting that while the
data may be observational in nature, high risk of bias observational studies are not
driving the primary findings. Similarly, many important infectious diseases clinical issues
in critical care related to Staphylococcal infections have limited, or no, randomized
controlled trial data to guide clinician decision making, including: AUC versus trough
based dosing for vancomycin,23 nephrotoxicity risk of combination vancomycin and
piperacillin-tazobactam,125 cefazolin versus nafcillin for methicillin-susceptible
Staphylococcus aureus infections,126 and combination therapy for MRSA bacteremia.127
Second, one emerging observation is AUC-based dosing of vancomycin is associated
with reduced AKI compared to trough-based dosing, particularly given growing evidence
that trough values correlate poorly with AUC and troughs of 15-20 mcg/mL may provide
supratherapeutic exposure when assessed by the AUC.36,128 The possibility cannot be
ruled out that continuous infusion is associated with less AKI in our analysis because
continuous infusion regimens in these studies perhaps better controlled AUC within a
therapeutic range without predisposing to elevations in AUC (despite trough
concentrations at goal). However, the sensitivity analysis in the cohort targeting lower
trough concentrations in the intermittent groups still found a statistically significant
difference favoring a continuous infusion. Third, the AKI definition was not universal
among all included studies and most were based on serum creatinine as the primary
classification. However, the sensitivity analysis including studies with a definition of
50% serum creatinine increase from baseline or 0.3-0.5 mg/dL increase from baseline
(including 9 of the 11 studies) essentially mirrors the Kidney Disease Improving Global
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Outcomes (KDIGO) stage 1 serum creatinine criteria for AKI,79 and the point estimate in
Figure 5.6 mirrors that of the primary analysis. Finally, variations in the empiric dosing
protocol and adjustment strategies introduce additional heterogeneity among studies. For
example, more frequent loading doses in the continuous infusion group may have
contributed to the association with greater percentage of pharmacokinetic target
attainment (as defined by the dosing protocol used) with the continuous infusion
strategy.129 It is also important to note that pharmacokinetic attainment was not the
primary outcome of our systematic review and meta-analysis, thus other studies may
exist that studied pharmacokinetic target attainment in critically ill patients, but did not
include the primary outcome of AKI, that were excluded from our analysis.
Future studies should consider urinary biomarkers of tubular damage, such as
KIM-1, as a mechanistic outcome comparing the two dosing strategies. Given that
critically ill patients face many other potential insults to the kidney, controlling for
severity of illness, use of vasopressors, concurrent nephrotoxins, relevant past medical
history, and other factors should be carefully considered. AUC monitoring should be used
as the dosing target as opposed to a single level or trough evaluation, with a goal of 400600 mg*hr/L.23 A standardized definition and grading of AKI as proposed by KDIGO
should be employed,79 potentially with additional risk stratification as assessed by urinary
biomarkers of tubular injury and dysfunction.130
5.5 Conclusions
In a meta-analysis of critically ill adults receiving vancomycin, continuous infusion was
associated with a 53% reduction in the odds of AKI compared to intermittent infusion.
Given the growing recognition that peak levels, when administered via intermittent
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infusion, may be contributing to sub-clinical and clinical AKI, additional prospective
trials of continuous vs. intermittent infusion of vancomycin with AUC-targeted dosing
are warranted to optimize the safety of vancomycin for critically ill patients.
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Table 5.1 Study Demographics
Reference

Study Design

ICU Type

Infection

Definition of Acute
Kidney
Injury/Nephrotoxicity

Pathogen: 33.3%
≥0.5 mg/dL or ≥50%
Burn
Gram-positive
increase in SCr
Source: Multiple
Pathogen: 21% SCr increase 1.5 times
Bissell
Cohort
MRSA
baseline or absolute
Trauma
Source:
2018
(retrospective)
increase in SCr ≥ 0.3
Multiple
mg/dL
SCr increase of ≥ 0.3
mg/dL or 1.5 to 2 times
Pathogen: Nonincrease from baseline
Duszynska
Cohort
MRSA gram
on at least 2 consecutive
Unspecified
2016
(prospective)
positive
days and/or urine output
Source: Multiple
< 0.5 mL/kg/hr for >6
hours
Pathogen:
SCr increase ≥ 50%;
Hanrahan
Cohort
11% MRSA
All
eGFR decrease ≥ 25%;
Source:
2014
(retrospective)
SCr ≥ 3.95 mg/dL
Unspecified
≥ 50% increase in SCr;
Pathogen:
SCr > 0.5 mg/dL from
Cohort
Hong 2015
Neurosurgical 16% S. aureus
baseline; ≥50%
(retrospective)
Source: Multiple decrease in CrCl on at
least 2 consecutive days
Pathogen:
≥50% increase in SCr in
Staphylococcus 48 hours; ≥0.3 mg/dL
Hutschala
Cohort
Cardiac
species
rise in SCr in 48 hours;
2009
(retrospective) surgery ICU
Source:
<0.5 mL/kg/hr urine
Multiple
output > 6 hours

Cohort
Akers 2012
(retrospective)

Target (mg/L)

Loading Dose

CI

II

CI

II

20-25

Ctr=1520

None

None

15-25

Ctr=1520 mg/kg
20

15-20

Ctr=1520

NR

NR

Dosing Regimen
CI

II

3,000 mg/day 1,000 mg q8h

NR

30 mg/kg/day

NR

500 mg

25 mg/kg

30mg/kg/day

Nomogram
based on
weight and
CrCl

NR

NR

NR

NR

20-30

Ctr =1520 mg/kg
20

None

20-25

Ctr=15 20 mg/kg

20mg/kg

15-40
15 mg/kg q8mg/kg/day
24h
depending on depending on
CrCl
CrCl

36 mg/kg/day

60 mg/hr
(1440
mg/day)
Ctr: 51000Impaired
None
10
1250mg
renal
function: 40
mg/hr (960
mg/day)
21.6-57.6
Ctr: 15mg/kg/day
20 mg/kg
None
20
per
nomogram
500mg-2000
Ctr: 10Recommended
mg/day
1000mg
20
(details NR) depending on
CrCl

NR

Saugel
2013

Cohort
(retrospective)

Medical ICU

Unspecified

Need for renal
replacement therapy

15-25

Schmelzer
2013

Randomized
Clinical Trial

Trauma

Pathogen: NR
Source:
Pneumonia

SCr increase ≥ 50%
from baseline

15-25

Tafelski
2015

Cohort
(prospective)

Surgical ICU

Pathogen:
Not reported
Source:
Multiple

RIFLE criteria for
injury, failure, or loss

15-20

Wysocki
1995

Cohort
(prospective)

Unspecified

Pathogen:
MRSA
Source:
pneumonia,
bacteremia

20-30

Cpk=2040
15 mg/kg
Ctr=510

None

30 mg/kg/day

15 mg/kg
q12h

MedicalSurgical

Pathogen:
Methicillinresistant
Staphylococci
Source:
Multiple

Rise in SCr of 0.5
mg/dL or more if initial
level <3 mg/dL
Rise of 1 mg/dL or
more if initial level ≥ 3
mg/dL
50% increase in SCr
from day treatment was
started to end of
treatment

20-25

Ctr=1015mg/kg
15

None

30 mg/kg/day

15 mg/kg
q12h

Wysocki
2001

Randomized
Clinical Trial
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1000-2000
mg daily

15 mg/kg
q12h
500 mg q6h
or 1000 mg
q12h

Table 5.1 (continued)
Regime
Reference n (%)
CI

II

Akers 2012 49 51
Bissell
2018

Age (years)
CI

II
35.6
40.8 ±
±
19.8
17.2

50 50

43 ±
16

Duszynska
50 50
2016

62 ±
14

Hanrahan
2014

46 28c

Weight (kg)

Males
(%)

CI

II

CI II

89.4 ±
20.8

91.3 ±
21.5

91 90

61
59 (44(4869)
71)

75 (66- 75 (6864 67
85)
88)

56 ±
15.5

56.3
±
14.8

Hutschala
80 20
2009

59 ±
14

59 ±
75 ± 16 75 ± 16 61 70
14

65 ±
13

61 ±
15

69 31

CI

II

0.99 ± 0.97 ±
0.39
0.40

0.7
0.81
52 ±
87 ± 26 87 ± 20 87 73 (0.54- (0.6818
0.88)
1.1)
54 ±
1.0 ± 1.1 ±
77 ± 11 84 ± 10 81 86
15
0.6
0.7

Hong 2015 50 50

Saugel
2013

Baseline Serum
Creatinine
(mg/dL)

79.8 ±
18.3

82.3 ±
25.5

54 55

75 (50- 70 (4661 67
130)
100)

NR

NR

CI
2,500
mg ±
720 mg
2500
(19913000)
2219 ±
476
1700 mg
(12002100
mg)

0.92 ± 0.98 ± 2572 ±
0.31
0.49 784
0.9 ±
0.5

0.9 ±
0.7

NR

NR

Concomita
Mean/Median
nt
Duration
Nephrotoxi
a
(days)
ns (%)
II
CI
II
CI
II
2,290
13.3
12.4 ±
mg ±
±
NR NR
11.8b
630mg
12.4b
2000
3.8
6.8
(2000- (2.7- (3.5- 98.7 97.3
2698)
6.8) 9.2)
2466 ±
7 (77 (7-8)
86 100
930
10)
1500 mg
4.4
5.3
(900(3.4- (2.5- 72d 45d
2200
10.3) 7.3)
mg)

Mean/Median
Daily Dosea

1935 mg
± 688
mg
960 mg
(5261723
mg)

2779 ± 10.4 ± 14.1
NRe NRe
1205
7.8 ± 8.8
1325 mg
± 603 9 ± 6
mg
500 mg
(1806 (21000mg 21)
]

8.5 ± 71.4
73.3d
d
7
7 (159d
24)

57d

41.3
82.8 ± 87.2 ±
0.72 0.79 ±
±
89 89
NR
NR
NR
NR NRe NRe
21.2
19.6
±0.20 0.21
17.9
67
Tafelski
70 (60- 80 (7060 (507 (4- 5 (361 39
(4859 69 NR
NR
NR
NR
NR NR
2015
90)
90)
70)
11)
8)
75)
Wysocki
61 ± 67 ±
1.28 ± 1.62 ± 24 ±
12 ±
16 ± 16 ±
50 50
68 ± 10 70 ± 7 77 77
NR NR
1995
17
13
0.93
0.63 14mg/kg 5mg/kg
10
13
Values Values
NR but NR but
Wysocki
64 ± 62 ±
1.1 ± 1.0 ±
14 ±
similar similar 13 ± 5
51 49
73 ± 15 69 ± 17 69 60
59
74
2001
13
16
0.5
0.4
6
between between
groups groups
ICU = intensive care unit; CI = continuous infusion; II= intermittent infusion; MRSA = Methicillin-resistant Staphylococcus aureus;
SCr = serum creatinine; Cpk = peak concentration; Ctr = trough concentration; NR = not reported
Schmelzer
51 49
2013

40.3 ±
16.4

Means reported as means ± standard deviation and medians as median (interquartile range)
Reported only for GPC bacteremia cohort
c
Not add up to 100 due to classification of a mixed category as well
d
Included vasopressors
e
Not reported but all patients with nephrotoxicity were receiving concomitant nephrotoxins
a

b
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Table 5.2 Risk of Bias Assessment
Study

Randomized Clinical Trials
Cochrane Risk of Bias Assessment
Random
Sequence
Generation

Allocation
Concealm
ent

Blinding
of
Participa
nts and
Personne
l

Blinding of
Outcome
Assessment

Incomplete
Outcome
Data

Schmelzer
2013

Low

Unclear

Wysocki
2001

Low

Low

Selective
Reporting

Other Bias

High

Low

High

High

High

High

Low

High

Unclear

Low

Observational Studies
Newcastle-Ottawa Scale
Representati
veness
Of the
exposed
cohort

Selection
of the nonexposed
cohort

Ascertai
nment of
exposure

Demonstrati
on that
outcome of
interest was
not
presented at
start of
study

Comparabilit
y of cohorts
on the basis
of design or
analysis

Assessment
of Outcomes

Was followup long
enough for
outcomes to
occur?

Adequacy
of followup of
cohorts

Total

Akers 2012

*

*

*

0

0

*

*

*

6

Bissell 2018

*

*

*

0

0

*

*

*

6

Duszynska
2016

*

*

*

0

**

*

*

*

8

Hanrahan
2014

*

*

*

0

**

*

*

0

7

Hong 2015

*

*

*

0

**

*

*

*

8

Hutschala
2009

*

*

*

*

**

*

*

*

9

Saugel 2013
Tafelski 2015

*
*

*
*

*
*

0
0

0
*

*
*

*
*

0
*

5
7

Wysocki
1995

*

*

*

0

*

*

*

*

7
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Table 5.3 Study Outcomes
Reference

CI

II

7/68

13/70

(10.3%)

(18.6%)

16/75

32/75

(21.3%)

(42.7%)

Duszynska

5/21

8/21

2016

(23.8%)

(38.1%)

161/653

77/390

(24.7%)

(19.7%)

10/65

14/65

(15.4%)

(21.5%)

33/119

11/30

(27.7%)

(36.7%)

Akers 2012

Bissell 2018

Hanrahan 2014

Hong 2015

Hutschala 2009

7/94
(7.4%)

Schmelzer

1/28

3/27

2013

(3.6%)

(11.1%)

20/76

17/49

(26.3%)

(34.7%)

2/13

3/13

(15.4%)

(23.1%)

10/61

11/58

(16.4%)

(19.0%)

Wysocki 1995

Wysocki 2001

a

12/52

Saugel 2013

Tafelski 2015

Mortality

Acute Kidney Injury/
Nephrotoxicity

(23.1%)

Pharmacokinetic Target
Attainment %

ORa
0.50
(0.19-1.35)

0.36
(0.18-0.75)

CI

II

13/68

14/70

(19.1%)

(20%)

7/75

13/75

(9.3%)

(17.3%)

NR

NR

172/653
(26.3%)

49/390
(12.6%)

10/65

13/65

(15.4%)

(20.0%)

0.51
(0.13-1.93)
0.12
(0.04-0.35)

0.66
(0.27-1.62)

0.66
(0.28-1.54)

25/119
(21%)

6/30
(20%)

0.27
(0.10-0.73)

NR

NR

0.30
(0.03-3.04)

NR

NR

15/76

11/49

(19.7%)

(22.4%)

5/13

6/13

(38.5%)

(46.2%)

21/61

19/58

(34.4%)

(32.8%)

0.67
(0.31-1.47)

0.61
(0.08-4.41)

0.84
(0.33-2.15)

ORa

CI

II

0.95
(0.41-

21/68
(30.9%)

16/70
(22.9%)

45/75
(60%)

30/75
(40%)

NR

15/21
(71.4%)

9/21
(42.9%)

1.36
(0.90-

NR

NR

26/65
(40%)

14/65
(21.5%)

NR

NR

NR

NR

NR

NR

16/28
(57.1%)

2/27

2.19)
0.49
(0.181.31)

2.05)
0.72
(0.291.80)
1.06
(0.392.89)

0.85
(0.35-

(7.4%)

NR

NR

NR

NR

NR

NR

2.04)
0.73
(0.153.47)
1.08
(0.502.31)

Adjusted OR reported with 95% confidence intervals if available from study; otherwise manually calculated from raw data
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Figure 5.1 Study Inclusion and Exclusion
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Figure 5.2 Funnel Plot to Assess Publication Bias

94

Figure 5.3 Forest Plot for Primary Outcome of Acute Kidney Injury/Nephrotoxicity
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Figure 5.4 Sensitivity Analysis: Impact of Study Design on Outcome of AKI
Randomized Controlled Trials (n=2)

Observational Studies (n=9)
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Figure 5.5 Sensitivity Analysis: Impact of Risk of Bias on Outcome of AKI
Low Risk of Bias (n=8)

High Risk of Bias (n=3)
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Figure 5.6 Sensitivity Analysis: Impact of AKI/Nephrotoxicity Criteria on Outcome of
AKI
Less Severe Definition: 50% Serum Creatinine Increase From Baseline or 0.3-0.5 mg/dL
Increase From Baseline (n=9)

More Severe Definition: Injury, Failure, or Loss Criteria or Need for Renal Replacement
Therapy (n=2)
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Figure 5.7 Sensitivity Analysis: Assessment of Vancomycin Trough Target on Outcome
of AKI
Intermittent Trough Target: 15-20 mg/L (n=6)

Intermittent Trough Target: 5-15 mg/L (n=4)
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Figure 5.8 Cumulative Meta-Analysis by Year
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Figure 5.9 Assessment of Vancomycin Infusion Strategy on Mortality
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Figure 5.10 Assessment of Vancomycin Infusion Strategy on Pharmacokinetic Target
Attainment

102

CHAPTER 6 POPULATION PHARMACOKINETIC MODEL OF CONTINUOUS
INFUSION VANCOMYCIN

103

6.1 Introduction
In a recent survey of critical care practitioners, continuous infusion vancomycin
was identified as rarely used by 94.2% of respondents.75 Continuous infusion
vancomycin offers many advantages to intermittent infusion, including fewer
concentration assessments and less complex mathematical calculations for AUC
monitoring,131 greater consistency in steady state concentrations,132 and importantly,
potentially less acute kidney injury.70 A number of population pharmacokinetic models
have been developed for vancomycin administered via intermittent infusion in critically
ill patients.133 However, likely given the low reported frequency of use, less
pharmacokinetic modeling has been performed on continuous infusions of vancomycin in
this patient population.134 In our recent meta-analysis of continuous versus intermittent
infusion of vancomycin in critically ill adults,70 we noticed that while intermittent
infusions of vancomycin are typically dosed via nomogram, it was less common to
personalize dosing for continuous infusion and a dose of 30 mg/kg/day was most
commonly used. When comparing these two infusion strategies head-to-head, it seems
necessary that we would compare precise dosing of intermittent infusion with precision
dosing of continuous infusions. Accordingly, we sought to develop a population
pharmacokinetic model of continuous infusion vancomycin in critically ill adults.
6.2 Methods
6.2.1 Study Design
This was a prospective, observational study of continuous infusion vancomycin in
a medical intensive care unit (ICU) of a tertiary care, academic referral center from June
2019 to February of 2020. Vancomycin dosing and monitoring at the University of
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Kentucky is established by a Pharmacy and Therapeutics committee approved protocol
that authorizes pharmacists to adjust doses and order vancomycin concentrations. As part
of our institutional shift from trough to AUC-based monitoring,94 continuous infusion
vancomycin was instituted in the protocol for consideration in critically ill patients,
patients requiring >4,000 mg vancomycin per day, or those unable to obtain therapeutic
AUC on intermittent infusions. The decision to use continuous or intermittent infusion at
this time was based on the discretion of the pharmacist dosing and monitoring
vancomycin. Continuous infusion was only advised for use with patients deemed to have
stable renal function, and a loading dose of vancomycin 25 mg/kg was recommended if
employing a continuous infusion. Administration via a central line was recommended if
available, but based on other data using < 6 mg/ml concentrations, peripheral
administration was allowed.113 Adult patients were prospectively identified during this
time period, and included if they received a continuous infusion of vancomycin and had
serum vancomycin concentrations drawn during routine clinical care. Patients requiring
continuous renal replacement therapy were excluded. The study was approved by the
Institutional Review Board at the University of Kentucky with a waiver of informed
consent (#56908).
6.2.2 Data Collection
Data were collected as documented in the electronic medical record. All doses,
time stamps, and vancomycin serum concentrations were extracted to build the model
data file. Covariates collected for evaluation in the pharmacokinetic model included: age,
race, sex, height, weight, Sequential Organ Failure Assessment score, serum creatinine,
creatinine clearance (Cockcroft-Gault95 unless >125% ideal body weight then Salazar105

Corcoran96), serum blood urea nitrogen (BUN), serum sodium, serum chloride, serum
phosphorous, serum albumin, presence of cirrhosis, norepinephrine equivalents, and
cumulative fluid balance in hospital stay.
6.2.3 Laboratory Analysis
Serum vancomycin samples were analyzed in the hospital’s clinical laboratory using a
Roche Cobas kinetic interaction of microparticles in a solution (KIMS)-based
immunoassay (Roche Diagnostics Corporation, Indianapolis, IN). All other laboratory
parameters were obtained from documentation during routine clinical care.
6.2.4 Pharmacokinetic Modeling
Pharmacokinetic modeling was performed in Monolix using non-linear mixed effects
modeling with the Stochastic Approximation Expectation-Maximization (SAEM)
algorithim.135,136 Complete data were present for all doses and concentrations assessed.
Covariate values present at the time of initial vancomycin dose were used for covariate
modeling in Monolix.
6.2.5 Structural Model
The structural model for the data was determined by testing one- and two-compartment
models, with elimination rate constant or clearance models, and with linear or MichaelisMenten elimination assuming lognormal distributions of parameters with random effects.
Parameter estimation is based on minimizing the objective function value (OFV) using
maximum likelihood estimation.60,137 Because more complex models with additional
parameters offer more degrees of freedom for the model to take different shapes and
therefore better able to describe the data, it is necessary to account for the additional
parameters when comparing structural models using the Akaike information criterion and
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Bayesian information criterion (BIC) with the following where OBJ is the minimum
OFV, ηp is the number of parameters in the model, and N is the number of data
observations.60
AIC = OBJ + 2 ⸱ ηp
BIC = OBJ + ηp ⸱ Ln(N)
Since BIC penalizes for greater model complexity, and therefore may be preferable when
data are limited, we primarily used BIC for comparing structural models in addition to
visual review of observed vs. predicted plots, scatter plot of residuals, and individual
subject model fits.60 We used the classification of Kass and Raftery to assess model
differences in BIC, with differences of >10 deemed “very strong” evidence in factor of
the model with the lower BIC.60,138
6.2.6 Covariate Selection
The relationship between covariates and the parameter estimates was assessed with
Pearson’s correlation tests or analysis of variance (ANOVA) for continuous and
categorical variables, respectively. Using power law relationships, continuous covariates
were log-transformed using the following formula: log (covariate divided by the
weighted mean of the dataset). Clearance and volume were allometrically scaled for
weight using fixed coefficients of 0.75 and 1, respectively.139,140 Covariate selection was
further informed by the COnditional Sampling use for Stepwise Approach based on
Correlation tests (COSSAC) algorithm in Monolix.135
6.2.7 Error Model
Once the covariates for inclusion were identified, the residual error model was developed
using the Stochastic Approximation for Model Building Algorithm in Monolix testing a
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constant, proportional, or combined error model.135,141 Reiterations of the model were
performed until the optimized model was found as assessed using BICc.
6.2.8 Final Model
The final model was selected based on the change in OBJ, with a reduction of 3.84
considered statistically significant (p<0.05, chi squared distribution, degree of freedom
=1), lowest AIC and BIC scores, goodness-of-fit checks including individual patient
review of observed vs. predicted, between subject variability associated with population
estimates, and the rule of parsimony.
6.2.9 Simulations
Using population estimates from the final population pharmacokinetic model, MonteCarlo simulations were performed in Simulx142 assessing AUC target attainment of 400600 mg⸱hr/L for three discrete time intervals: AUC0-24, AUC24-48, and AUC48-72. These
time intervals were selected given the importance of early AUC target attainment within
initial days of therapy, but also since empiric therapy in the ICU setting is often 48-72
hours in duration. Given vancomycin is typically dosed on a mg/kg basis clinically, and
extremes of weight may lead to issues of dose capping, we simulated individuals of more
typical weights of 70-100 kg. Drawing from a similar distribution of age (mean 55 ± 16)
and BUN (23.1 ± 16.6 mg/dl) as our population, we first simulated 1000 patients with the
typical recommendation of a 25 mg/kg loading dose and 30 mg/kg/day maintenance dose
to begin immediately following the completion of the loading dose. The initiation timing
of the maintenance dose in relation to the loading dose was examined to determine the
impact of delaying the start of the maintenance dose on AUC target attainment. Using
identified covariates from the population pharmacokinetic model, we attempted to
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develop a simplified dosing nomogram for continuous infusion vancomycin considering
these covariates. This process was iteratively repeated in 5 mg/kg/day intervals for the
loading and maintenance doses, seeking the combination that maximized AUC target
attainment within 72 hours while attempting to limit the frequency of supratherapeutic
AUCs at any given time point to <25% if possible.
6.3 Results
As noted in the inclusion criteria, all patients were critically ill and admitted to the
medical ICU. Patient demographics are shown in Table 6.1. The data consist of 239
dosing events and 124 vancomycin concentrations from 50 critically ill patients. Nine
patients had two serum concentrations assessed following the loading dose, while an
additional eight patients had a single serum concentration assessed following the loading
dose, prior to any subsequent dosing.
6.3.1 Structural Model
All structural models assessed are shown in Table 6.2. The structural model
selected was a one (1) compartment model using the parameters volume (V) and
clearance (CL). As seen in Table 6.2, we considered the difference in BIC of >10
between this and the next closet model very strong evidence in favor of this model as
described in our methods.60,138 Visual inspection revealed acceptable observed vs.
predicted concentrations, individual fits of the model to concentrations from each subject,
appropriate distribution of the residuals, and acceptable relative standard errors (RSEs) of
the parameter estimates.
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6.3.2 Covariate Selection
Figure 6.1 shows correlations between covariates and the parameter estimates for V and
CL. Statistical comparisons are shown in Table 6.3. In addition to allometrically scaled
weight using fixed values of 0.75 and 1 for clearance and volume, respectively,
covariates retained in the final model included serum BUN and age with significant
effects on clearance.
6.3.3 Error Model
The best residual error model identified was the proportional error model shown below,
where Cc is the predicted concentration, b represents the error model parameter, and e is
a standard normal random variable that generates the residual error.141
Observation = Cc + b*Cc * e
6.3.4 Final Model
Given significant between subject variability for volume when modeled as a random
effect, volume was modeled as a fixed effect in the final model using the allometrically
scaled weight. The final model is shown below, where ηCl is the random effect of
clearance.
log(V) = log (Vpop) + βV_logWT*logWT
log(CL) = log(CLpop) + βCl_logAGE * logAGE + βCl_logBUN* logBUN + βCl_logWT *logWT +

ηCL
The final population parameter estimates for the model are shown in Table 6.4. The
observed vs. predicted concentrations are shown in Figure 6.2 for the population
predictions (R2=0.26) and individual predictions (empirical Bayes estimates) (R2= 0.60;
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outlier proportion=5.65%). The residuals are appropriately distributed as shown in
Figures 6.3 and 6.4. The distribution of CL is shown in Figure 6.5 (shrinkage -7.63%).
Distribution of the CL standardized random effect is shown in Figure 6.6 and is
appropriately centered around zero. Assessment of model convergence was appropriate
(Figure 6.7).
6.3.5 Simulations
Using population parameters and the final population pharmacokinetic model and
simulating 1000 patients weighing between 70-100 kg with the traditional
recommendation of a 25 mg/kg loading dose followed by 30 mg/kg/day continuous
infusion, we observed a high frequency of supratherapeutic AUC0-24, AUC24-48, and
AUC48-72 values (Table 6.5). This is shown graphically in Figure 6.8, where the median
concentration of the continuous infusion is just under 30 mg/L, while a continuous
infusion steady state concentration of 17-25 mg/L (multiplied by 24) corresponds to AUC
values within 400-600 mg⸱hr/L. We observed that extending the time from the start of the
loading dose to initiation of the continuous infusion maintenance dose allowed for
optimization of AUC across the time periods evaluated, particularly avoiding
supratherapeutic AUC0-24 (Table 6.5). Using the iterative process described to maximize
AUC target attainment while attempting to keep the frequency of supratherapeutic AUC
exposure to <25% at each time period, if possible, we determined that the optimal
regimen of vancomycin continuous infusion for a typical individual weighing 70-100kg
was a 20 mg/kg loading dose (dosed on actual body weight) followed by a continuous
infusion of 20 mg/kg/day to begin 12 hours following the initiation of the loading dose.
In a simulated population with a similar distribution of age and serum BUN as our
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population used for model development, this regimen achieved AUC target attainment at
24, 48, and 72 hours 58.4%, 40.7%, and 37.9% of the time, respectively, while
minimizing the frequency of supratherapeutic AUC exposure to under 25%. The
simulated concentration versus time profile and AUC0-24, AUC24-48, and AUC48-72 for this
regimen are shown in Figures 6.9 and 6.10, respectively.
Given that serum BUN, age, and weight were identified as significant covariates,
we attempted to develop a simplified dosing nomogram using these covariates. Based on
our simulations, we designed the maintenance dose of continuous infusion to begin 12
hours following the start of the loading dose. Age and BUN were categorized as above or
below their mean values from the covariate distribution and simulated in the following
categories: age (18-55), age (56-80), BUN (≤ 23 mg/dl) and BUN (24-75 mg/dl). The
two-by-two nomogram created that maximized AUC target attainment and attempted to
limit supratherapeutic AUC frequency to <25% is shown in Table 6.6. Given that we
modeled volume as a fixed rather than random effect, we kept the 20 mg/kg loading dose
constant in the proposed nomogram. This simplified nomogram demonstrates improved
simulated AUC0-24, AUC24-48, and AUC48-72 target attainment compared to the universal
20mg/kg loading, 20 mg/kg/day maintenance regimen derived in Table 6.5.
6.4 Discussion
Using data from 50 patients in a medical ICU receiving continuous infusion
vancomycin, we were able to fit a population model to the data that reasonably explained
the vancomycin concentrations observed. A one-compartment model with clearance and
volume was the best fit, with covariate adjustments for serum BUN, age, and weight.
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In 2011, Roberts and colleagues published a population pharmacokinetic model of
continuous infusion vancomycin.143 Similar to our model, the final model was a onecompartment model with clearance and volume. Total body weight was a significant
parameter in describing volume of distribution and urinary creatinine clearance best
described vancomycin clearance. Compared to our model, their estimate of population
clearance was slightly higher (mean 4.58 L/hr). While the R2 of our observed vs.
individual predicted concentrations was similar at 0.60 in each study, our observed
population vs. predicted concentrations was improved (R2=0.26 vs. 0.07), suggesting our
model may perform superior for empiric dosing of vancomycin in this population.143 The
exact type of ICU patient in the model (surgical vs. medical) developed by Roberts et
al143 is unclear, but may explain their higher clearance. For example, trauma and
neurocritically ill patients may be at a higher likelihood of augmented renal clearance and
have additional comorbidities impacting vancomycin clearance compared to a medically
critically ill patient population such as ours. A similar one-compartment model was
developed in 2017 parameterized by clearance and volume.144 Creatinine clearance was
included as a covariate influencing vancomycin clearance and total body weight as a
covariate impacting volume. Additionally, mechanical ventilation, tested for its potential
biologic rationale of lowering cardiac output and renal blood flow, was included with a
significant covariate effect on vancomycin clearance.144
Several other comparisons between these prior models and our model deserve
discussion. First, although components of typical creatinine clearance equations including
age and weight were included in our model, creatinine clearance was not a significant
covariate of vancomycin clearance as it was compared to the prior two models
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discussed.143,144 Models can only describe the data they are developed from, and patients
in our cohort likely represent a population deemed to have relatively stable renal function
for the pharmacist dosing to use continuous rather than intermittent infusions, which is
supported by the baseline serum creatinine and BUN from Table 6.1. From this cohort
however, we did observe BUN as the strongest covariate effect on vancomycin clearance.
BUN was not evaluated in the prior models developed.143,144 BUN is often concomitantly
measured with serum creatinine as a measure of renal function; approximately 85% of the
body’s urea is eliminated by the kidney.145 Just as serum creatinine is identified as a
relatively insensitive marker to loss of renal function, several factors in critical care can
influence BUN including protein intake and liver disease to name a few.145 Even though
BUN is a recognized poor marker of GFR, its elevation is associated with mortality in
several disease states and may reflect on tubular function of the kidneys to some extent as
well, which is also known to influence vancomycin secretion.146,147 Second, unlike other
models that modeled volume as a random effect, the between subject variability in
volume led us to model volume as a fixed effect. Despite our efforts to capture potential
measurable covariate influencers of this parameter, including cumulative fluid balance,
we were unable to account for the variability of this parameter, which is known to exhibit
significant variability in critically ill patients, with both inter-and intra-patient variability
depending on clinical status.148
Our simulations performed using this model provide additional insights into
optimal continuous infusion vancomycin dosing. Although it is recognized that a loading
dose of vancomycin is advisable when using continuous infusions due to the potential
delay in reaching appropriate concentrations with a continuous infusion, the optimal
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combination and relative timing of loading and maintenance initiation are not abundantly
clear based on published literature. Updated vancomycin consensus guidelines
recommend a loading dose of 20-35 mg/kg vancomycin (up to 3,000mg) if considering
intermittent dosing, although at the time of vancomycin initiation it may be unclear
whether intermittent or continuous infusion regimen will be pursued, particularly if
started in the emergency department for example where the patient is originally
assessed.23 If using continuous infusion vancomycin, consensus recommendations
suggest consideration of a loading dose of 15-20 mg/kg and a maintenance dose of 30-40
mg/kg/day.23 Our findings agree with a component of this recommendation, in that we
found greater AUC target attainment over 72 hours, with reduced frequency of
supratherapeutic AUC with a lower loading dose of 20 mg/kg. Additionally, our
simulations suggested that delaying the initiation of the maintenance dose to 12 hours
following the start of the loading dose also maximized AUC target attainment while
minimizing supratherapeutic AUC0-24 that may have been due to administration of the
maintenance dose beginning immediately following the loading dose. This is highly
clinically relevant and suggests that the decision to initiate maintenance dosing for
continuous infusion can be delayed for 12 hours while other important elements occur,
including any transitions of care and further evaluation of intravenous access, which may
be a critical consideration to use continuous vancomycin or not. Contrary to the model by
Roberts143 and consensus guideline recommendations,23 our simulations suggest
significantly lower maintenance doses of vancomycin in medically critically ill
individuals. While we determined a maintenance dose of 20 mg/kg/day optimized the
probability of AUC target attainment while minimizing supratherapeutic exposure on
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average, we saw much greater success with the simplified nomogram we developed using
weight-based dosing with the covariates of serum BUN and age that we derived from our
model. In a previous study involving a similar medically critically ill population, we
found AUC target attainment to only be 32.4% with empiric intermittent infusion dosing,
which was increased to 58.6% with the use of first-dose pharmacokinetics.149 Our
proposed nomogram, if validated, would provide potentially even greater precision and
accuracy, with far fewer labor and laboratory costs, to optimize AUC target attainment
over the initial days of therapy.
Our study has several strengths, including the vancomycin concentration-topatient ratio of almost 3:1 and large number of biologically relevant covariates
investigated for a drug known to exhibit substantial inter-patient variability. Our final
population pharmacokinetic model was able to well-describe the observed versus
individual predicted serum vancomycin concentrations. We simulated clinically relevant
scenarios to help inform optimal dosing of continuous infusions and were able to derive a
simplified nomogram that could assist with empiric vancomycin dosing when given via
continuous infusions. Several limitations deserve mention as well. First, these are data
from a single ICU at a single center and a relatively small number of patients. Second,
this model, including our proposed nomogram, has not been externally validated. While
the model and covariates deserve additional study for validation, the covariates in our
model are static on the day of vancomycin initiation and changes during critical illness
may influence the impact of these covariates have on the final model. More sophisticated
approaches with covariate modeling may allow us to increase the precision of the model.
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6.5 Conclusion
We developed a population pharmacokinetic model of continuous infusion
vancomycin in critically ill adults which adequately described the data using a onecompartment model with volume and clearance, and covariates of serum BUN, age, and
weight. A simplified dosing nomogram optimized AUC target attainment over the initial
72 hours of therapy using these covariates. Future research to validate this model can
help to inform precision dosing of continuous infusions of vancomycin in critically ill
patients.
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Table 6.1 Patient Demographics at Time of First Vancomycin Dose
Patient Characteristic (n=50)
Descriptive Statisticsa
Age (years)
59 (46.5-68)
Race (% white)
46 (92%)
Sex (% male)
27 (54%)
Height (cm)
167.6 (162.9-177.8)
Weight (kg)
90.7 (64.2-109.1)
Sequential Organ Failure Assessment score
6 (5-9)
Serum creatinine (mg/dl)
0.8 (0.6-1.0)
Serum blood urea nitrogen (mg/dl)
20 (13-27)
Serum sodium (mmol/l)
140 (137-142)
Serum chloride (mmol/l)
104 (100-107)
Serum albumin (g/dl)
2.5 (2.0-2.9)
Serum phosphorus (mg/dl)
2.7 (2.2-3.4)
Cirrhosis (%)
8 (16%)
Norepinephrine equivalents (mcg/kg/min)
0 (0-0.03)
Net fluid balance (ml)
-102 (-906 to 798)
Initial vancomycin dose (mg)
2000 (1500-2500)
Initial vancomycin dose (mg/kg actual body
22 (17-24)
weight)
a
Reported as medians (interquartile range) or percentages
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Table 6.2 Evaluation of Structural Model
Run Compartment Elimination Parameters
01
1
Linear
V, k
02
1
Linear
V, Cl
03
1
MM
V, Km, Vm
04
2
Linear
V1, Q, V2, Cl
05
2
Linear
V, k1,2, k2,1, k
06
2
MM
V1, Q, V2,
Km, Vm
07
2
MM
V, k1,2, k2,1,
Km, Vm

OFV
829.8
815.6
826.7
813.5
814.0
812.7

AIC
841.8
827.6
842.7
833.5
834.0
836.7

BIC
853.3
839.1
858.0
852.6
853.1
859.6

BICc
856.9
842.7
862.6
858.1
858.6
866.0

822.1 846.1 869.0 875.4

OFV= -2 x log-likelihood; AIC= Akaike Information Criteria; BIC= Bayesian Information Criteria; BICc=
Corrected Bayesian Information Criteria; k=elimination rate constant; V= volume of distribution; Cl=
Clearance; MM=Michaelis-Menten; Km= Michaelis constant; Vm=maximum rate; V1= central
compartment; V2=peripheral compartment; Q=intercompartmental clearance; k1,2=rate of transfer from
central to peripheral compartment; k2,1=rate of transfer from peripheral to central compartment
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Table 6.3 Statistical Evaluation of Covariates with Random Effects
V
COEFF STATISTICS P-VALUE
LIVER

0.058

8.1e-1

RACE

0.76

4.73e-1

SEX

0.92

3.42e-1

AGE

0.023

0.16

8.75e-1

ALBUMIN

-0.0025

-0.018

9.86e-1

BUN

-0.2

-1.43

1.59e-1

CHLORIDE

-0.04

-0.28

7.82e-1

CRCL

0.16

1.13

2.66e-1

FLUID BALANCE 0.0064

0.044

9.65e-1

HT

0.052

0.36

7.21e-1

SODIUM

-0.2

-1.43

1.6e-1

PHOS

-0.2

-1.4

1.68e-1

SCR

-0.15

-1.02

3.15e-1

SOFA

-0.16

-1.09

2.79e-1

VASOPRESSORS

0.022

0.15

8.8e-1

WT

0.32

2.35

2.28e-2
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Table 6.3 (con)
CL
COEFF STATISTICS P-VALUE
LIVER

0.15

7.03e-1

RACE

0.046

9.55e-1

SEX

2.29

1.36e-1

AGE

-0.26

-1.89

6.43e-2

ALBUMIN

-0.015

-0.1

9.2e-1

BUN

-0.45

-3.48

1.08e-3

CHLORIDE

-0.12

-0.83

4.12e-1

CRCL

0.35

2.61

1.21e-2

FLUID BALANCE 0.17

1.2

2.35e-1

HT

0.24

1.75

8.71e-2

SODIUM

-0.18

-1.25

2.16e-1

PHOS

-0.28

-1.99

5.22e-2

SCR

-0.15

-1.05

2.99e-1

SOFA

-0.085

-0.59

5.55e-1

VASOPRESSORS

-0.14

-0.95

3.45e-1

WT

0.37

2.76

8.08e-3
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Table 6.4 Population Pharmacokinetic Parameter Estimates
Value
Standard error

Relative standard error
(%)

Fixed Effects
Vpop
βV_logWT

44.37

3.46

7.81

1

Clpop

4.18

0.2

4.74

βCl_logAGE

-0.35

0.13

38.3

βCl_logBUN

-0.3

0.074

25.2

βCl_logWT

0.75

0.28

0.037

13.5

0.26

0.022

8.26

Standard Deviation of the Random Effects
ωCl
Error Model Parameters
b
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Table 6.5 Area-Under-the-Curve Target Attainment for Tested Loading and Maintenance
Dose Combinations Using Monte-Carlo Simulations
Loading Dose
Maintenance Dose AUC0-24
AUC24-48
AUC48-72
Loading Dose Over 2.5 Hours Immediately Followed by Initiation of Continuous
Infusion
25 mg/kg
30 mg/kg/day
Goal: 8.2%
Goal: 27%
Goal: 21.5%
Sub: 10.5%
Sub: 8.2%
Sub: 10.4%
Supra: 81.3% Supra: 62.0% Supra: 65.9%
25 mg/kg
25 mg/kg/day
Goal: 11.3%
Goal: 30.5%
Goal: 35.3%
Sub: 10.9%
Sub: 15.6%
Sub: 16.8%
Supra: 77.8% Supra: 50.7% Supra: 44.2%
20 mg/kg
25 mg/kg/day
Goal: 20%
Goal: 34.2%
Goal: 38%
Sub: 13.2%
Sub: 16.4%
Sub: 16.4%
Supra: 66.8% Supra: 45.9% Supra: 41.7%
25 mg/kg
20 mg/kg/day
Goal: 16.4%
Goal: 32.8%
Goal: 37%
Sub: 12.2%
Sub: 33.3%
Sub: 36.2%
Supra: 71.4% Supra: 30.5% Supra: 22.9%
20 mg/kg
20 mg/kg/day
Goal: 30.4%
Goal: 33.4%
Goal: 33.5%
Sub: 15%
Sub: 35.7%
Sub: 41.8%
Supra: 54.6% Supra: 27.4% Supra: 21.2%
Loading Dose Over 2.5 Hours with Continuous Infusion Commencing 12 Hours
Following Start of Loading Dose
25 mg/kg
25 mg/kg/day
Goal: 33%
Goal: 38.5%
Goal: 37.4%
Sub: 16%
Sub: 18.7%
Sub: 16.8%
Supra: 51%
Supra: 38.8% Supra: 41.9%
20 mg/kg
25 mg/kg/day
Goal: 55.7%
Goal: 41.4%
Goal: 36.1%
Sub: 23.8%
Sub: 17.9%
Sub: 16.6%
Supra: 20.5% Supra: 36.4% Supra: 43.5%
20 mg/kg
20 mg/kg/day
Goal: 58.4%
Goal: 40.7%
Goal: 37.9%
Sub: 27%
Sub: 38.5%
Sub: 36.8%
Supra: 14.6% Supra: 16.6% Supra: 21.3%
Goal= at goal range of 400-600 mg⸱hr/L; Sub=below 400 mg⸱hr/L; Supra=Higher than 600 mg⸱hr/L
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Table 6.6 Proposed Dosing Nomogram and AUC Target Attainment
Age ≤ 55
Load: 20 mg/kg
Maintenance: 20 mg/kg/day

Age >55
Load: 20 mg/kg
Maintenance: 15 mg/kg/day

Category

BUN
>23

BUN
≤ 23

AUC0-24
Goal: 70%
Sub: 10.5%
Supra: 19.5%

AUC24-48
Goal: 53.3%
Sub: 26.2%
Supra: 20.5%

Load: 20 mg/kg
Maintenance: 30 mg/kg/day
AUC0-24
Goal: 60%
Sub: 33%
Supra: 7%

AUC24-48
Goal: 52.5%
Sub: 25.3%
Supra: 22.2%

AUC48-72
Goal: 49.3%
Sub: 25.2%
Supra: 25.5%

AUC48-72
Goal: 54%
Sub: 22%
Supra: 24%

AUC0-24
Goal: 62.2%
Sub: 3%
Supra: 34.8%

AUC24-48
Goal: 51.4%
Sub: 30.8%
Supra: 17.8%

AUC0-24
Goal: 71.2%
Sub: 15.2%
Supra: 13.6%

AUC24-48
Goal: 57.1%
Sub: 18.4%
Supra: 24.5%

Load: 20 mg/kg
Maintenance: 25 mg/kg/day

AUC48-72
Goal: 51.7%
Sub: 30%
Supra: 18.3%

AUC48-72
Goal: 51.8%
Sub: 16.9%
Supra: 31.3%

Simulation for patient weights 70-100 kg with maintenance dose beginning 12 hours following initiation of the loading dose.
BUN=serum blood urea nitrogen in mg/dl; Goal= at goal range of 400-600 mg⸱hr/L; Sub=below 400 mg⸱hr/L; Supra=Higher than 600
mg⸱hr/L
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Figure 6.1 Visual Evaluation of Covariate Relationship with Parameters
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Figure 6.1 (con)
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Figure 6.1 (con)
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Figure 6.1 (con)
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Figure 6.1 (con)
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Figure 6.1 (con)
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Figure 6.1 (con)
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Figure 6.1 (con)
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Figure 6.2 Observed Versus Predicted Population and Individual Concentrations
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Figure 6.3 Scatter Plot of Residuals for Final Model
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Figure 6.4 Distribution of Residuals for Final Model
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Figure 6.5 Distribution of Clearance
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Figure 6.6 Distribution of the Standardized Random Effect for Clearance
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Figure 6.7 Model Convergence
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Figure 6.8 Simulation of 1000 Patients of Typical Weight (70-100kg): 25 mg/kg Loading
Dose Followed by 30 mg/kg/day Continuous Infusion Starting Immediately Following
Loading Dose
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Figure 6.9 Simulation of 1000 Patients of Typical Weight (70-100 kg): 20 mg/kg Loading
Dose Followed by 20 mg/kg/day Continuous Infusion Starting 12 Hours Following Start
of Loading Dose
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Figure 6.10 Area-Under-the-Curve Simulation of 1000 Patients of Typical Weight (70100 kg): 20 mg/kg Loading Dose Followed by 20 mg/kg/day Continuous Infusion
Starting 12 Hours Following Start of Loading Dose
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Figure 6.10 (con)
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CHAPTER 7 DISCUSSION
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7.1 Aim 1
Our series of studies further inform precision drug delivery of vancomycin to
critically ill patients. We primarily were interested in evaluation of three techniques to
optimize drug delivery of vancomycin to critically ill patients: loading doses, first-dose
pharmacokinetic evaluation, and use of continuous rather than intermittent infusion. With
these strategies in mind, we began our work in aim 1 by first establishing practice
patterns of critical care clinicians related to vancomycin drug delivery.75 We found that
two of the drug delivery techniques that we were interested in studying were infrequently
used by practicing pharmacists in adult critical care units.75 Ninety four percent of our
survey respondents either rarely or only sometimes reported first-dose pharmacokinetic
evaluation to guide empiric dosing. Similarly, 98.6% of respondents reported rarely or
only sometimes using continuous infusions of vancomycin.75 If we were to demonstrate
improvements in precision drug delivery with these strategies, they could have the
potential to change the way vancomycin is delivered to critically ill patients throughout
the world based on our international survey showing a low prevalence of these practices.
We hypothesized that the frequency of loading doses would be more common given their
recommendation in vancomycin consensus guidelines,23 but still observed differential
reported frequency across various scenarios.75 Anticipating this based on a previous study
of vancomycin dosing practices,39 we sought to understand barriers for clinicians not
reporting more frequent use of loading doses and incorporate these hesitations into our
methods of aim 2. Indeed, a recent systematic review of implementation science research
in emergency medicine emphasized the importance of understanding barriers and
enablers in practice.150
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7.2 Aim 2
These findings were important to us in designing our study assessing vancomycin
loading doses in aim 2 and drove the inclusion of the primary outcome as clinical failure
and ensuring assessment of the secondary outcome of acute kidney injury. Simply put,
we sought to use this survey to ascertain clinician barriers to using loading doses, and
then use those concerns to try and design a study to test if those concerns were valid. Our
study in aim 2 of loading doses should alleviate concerns of nephrotoxicity from loading
doses that some clinicians had in our survey, but also likely supports their non-universal
use of a loading dose based on the lack of impact of observed clinical outcomes.75 This
highlights an important facet for further research in precision dosing of vancomycin, or
any medication for that matter, in clinical care: while optimization of pharmacokinetic
target attainment may be perceived to be beneficial by researchers and even guidelines, it
may be insufficient to persuade clinicians to universally adopt, particularly if the action is
accompanied by an increased workload, risks to the patient, or other disadvantages.
Indeed, since the release of the revised vancomycin consensus guidelines recommending
AUC over trough monitoring, this approach has been vigorously challenged in the
literature, the outcomes justifying use of AUC over trough monitoring, and resources
required to do so.151-154 Given the link of vancomycin-associated nephrotoxicity with real,
adverse clinical outcomes, including hospital readmissions and mortality and the
associated healthcare costs, the counter-debate is that vancomycin AUC monitoring
reduces the risk of nephrotoxicity.155 Even with the recognition that vancomycin-induced
nephrotoxicity most commonly occurs after 4-5 days of treatment,44 the consideration
that serum creatinine lags well-behind as an injury marker should give some concern
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regarding the injury potentially present earlier in therapy, including sub-clinical kidney
injury. Indeed, AUC monitoring may be cost-effective from the acute kidney injury
perspective alone.156 Interestingly, since completion of aim 2, another group has
evaluated the efficacy of vancomycin loading doses on critically ill patients with MRSA
pneumonia.157 Although the sample size was smaller, they also observed no difference in
any clinical efficacy outcomes.157 While we believe early AUC target attainment within
the initial days of therapy to still be critical from a safety perspective if nothing else, and
while our work does not provide definitive answers to this topic in the manner that a
randomized controlled trial would, we find it unlikely that future research on clinical
outcomes related to a single, initial dose of a drug in MRSA infection would yield
significant, patient-centered differences in outcomes.
7.3 Aim 3
As an early adopter of the transition to AUC-guided vancomycin dosing, our team
had clinical experience with vancomycin AUC dosing. Our anecdotal experience was that
traditional nomograms, or even clinical judgement used to guide empiric dosing of
vancomycin, was producing wide-ranging AUCs, very few of which were in the target
range. In aim 3, we confirmed this suspicion where we found that empiric dosing of
vancomycin in critically ill medical ICU patients achieved AUC target attainment at
steady state only 32.4% of the time.149 By using a first-dose pharmacokinetic approach in
patients with stable renal function, whereby 2 vancomycin concentrations were assessed
following the first dose to calculate patient-specific pharmacokinetic parameters, we
demonstrated this approach nearly doubled AUC target attainment at steady state to
58.6%.149 The advantages of this approach are relatively clear: using patient-specific
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dosing information assures more precise dosing and less likely to see variability in AUC.
If the patient has confirmed MRSA, this is advantageous to ensure appropriate AUC/MIC
attainment. If the therapy is empiric, this ensures the patient does not experience
unnecessary and risky extremes of vancomycin exposures given vancomycin’s
nephrotoxicity risk, particularly in critically ill patients with multiple kidney insults
present at any given time. The challenge to precision dosing of any medication, including
vancomycin, is that increasing precision will come with added cost of care. In the case of
Bayesian software programs, the cost is more tangible, direct, and known up-front, which
has been documented to hinder their use in practice.158 While this first-dose
pharmacokinetic approach does not carry those same costs, it does come with costs of
additional vancomycin concentrations and clinician effort to appropriately use the
information gained from very early concentration assessment. We suspect that clinicians
with a prior belief that early AUC target attainment is clinically relevant for efficacy and
safety outcomes will be attracted by this approach, while skeptical clinicians with low
prior beliefs about the value of early AUC target attainment are less likely to implement.
Since even the Bayesian methods rely heavily on the population pharmacokinetic models
incorporated and produce more accurate predictions once a patient’s own vancomycin
concentration has been incorporated into the Bayesian forecasting,159,160 one possible
expansion of this research in the future may include the assessment of a single
vancomycin concentration following the initial dose to better inform precise dosing of
vancomycin.
Using the first-order pharmacokinetic equations in clinical practice in the same
method that they are applied to pharmacokinetic studies is often challenging. Medication
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doses are often not administered at the exact time intervals, concentrations are not always
drawn at precise times, and other logistical issues. As our center instituted AUC
monitoring and developed the protocol for first-order pharmacokinetic equations, one
gains an appreciation of the sheer amount of inherent potential error in this math.
Variability occurs in not only the measurement of the vancomycin concentration from the
laboratory, but also assumptions about the occurrence of steady state, that levels are
obtained one half-life apart, back- and forward- extrapolations for concentrations that are
drawn late or early, respectively. Our interest in continuous infusions of vancomycin was
based not only on the ease of clinical use and relaxing some of the assumptions and
resources required to monitor (one concentration required for AUC assessment versus
two), but also due to an interest that continuous infusions of vancomycin may reduce the
risk of acute kidney injury.
7.4 Aim 4
As we noted in aim 4, our meta-analysis was unique in that it focused on critically
ill patients and used appropriate statistical techniques to account for the adjusted effect
estimates produced from some of the included studies. For example, pooling results from
critically ill patients and patients receiving home infusions of vancomycin is analogous to
pooling apples and oranges, a common critique of meta-analytic approaches in general.
The authors of prior cohort studies took care to adjust for confounding in their
presentation of the results, and it seems appropriate that these adjusted estimates (i.e. with
confounding minimized) would be appropriate to pool rather than unadjusted estimates
from non-randomized studies. In the meta-analysis of aim 4, we found that continuous
vancomycin infusions in critically ill patients were associated with more than a 50%
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reduction in the odds of acute kidney injury.70 As we continue to plan for future studies
comparing continuous versus intermittent infusion of vancomycin and kidney injury, this
estimate can help us derive a planned effect size for sample size calculations.
Similar effects of continuous versus intermittent infusion have been observed in
pre-clinical models as well. Supporting this concept of peak vancomycin concentrations
being a driver of kidney injury, rats were given equivalent daily doses fractionated over
various dosing intervals, including once, twice, three, or four times daily.46 Urinary
kidney injury molecule-1 (KIM-1) was approximately tripled in the once and twice daily
groups compared to the three and four times daily groups. In the same model,
vancomycin AUC and Cmax were both moderately or strongly correlated with urinary
KIM-1 and osteopontin.6 KIM-1 is a proximal tubule injury marker that has previously
been shown to correlate with histopathologic damage of the proximal tubules in
vancomycin induced kidney injury.121 Our group has studied KIM-1 in clinical AKI
studies and shown that in critically ill patients with AKI, urinary KIM-1 is approximately
two-fold higher 24-48 hours following AKI compared to critically ill patients without
AKI with measures at ICU admission.161 We have also shown that KIM-1 is associated
with the composite outcome of major adverse kidney events (death, renal replacement
therapy, or reduced kidney function) out to six months.161 This knowledge of KIM-1’s
behavior in clinically relevant AKI will also be useful in designing future studies
incorporating urinary biomarkers of kidney injury between patients treated with
continuous versus intermittent infusion.
In our systematic review and meta-analysis conducted in aim 4, one interesting
theme that appeared to emerge is that while intermittent dosing of vancomycin was
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typically carefully planned with nomograms, continuous infusions of vancomycin were
often based on a flat dose of 30 mg/kg/day.70 This discrepancy in careful, deliberate
dosing for one dosing strategy compared to a one-sized fits all approach for another
strategy appeared to be at odds with evaluation of precise vancomycin dosing. To our
knowledge, no cross-over study evaluating the clearance of vancomycin when
administered continuously versus intermittently has been completed, thus while we
assume that clearance is equivalent between the two dosing strategies based on principles
of first-order elimination, the kidneys may handle vancomycin differently depending on
the infusion strategy. Before we embark on future comparisons of continuous versus
intermittent infusions of vancomycin, it seemed necessary to develop dosing schemes of
continuous infusion vancomycin with the same level of effort that has been put into
developing dosing schemes of intermittent infusion of vancomycin.
7.5 Aim 5
In order to accomplish this, in aim 5 we studied 50 patients from the medical
intensive care unit with 124 associated vancomycin serum concentrations and used
dosing information obtained from clinical care to develop a population pharmacokinetic
model for continuous infusion of vancomycin in this patient population. We successfully
developed a one-compartment model to fit the data, parameterized by vancomycin
clearance and volume. We observed significant covariate effects of BUN, weight, and
age on vancomycin clearance that improved the fit of the model to the data, and
compared and contrasted our model to others published using continuous infusion
vancomycin in Chapter 6. We also derived important insights on the dosing of continuous
infusion vancomycin from our simulations, including a simplified nomogram for the
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maintenance dose and useful information on how the time interval from loading dose to
maintenance dose initiation impacts the AUC during this time period. Our finding that
delaying the initiation of the continuous infusion to 12 hours following the start of the
loading dose is not only highly clinically relevant as outlined in Chapter 6, but it is also
extremely useful for the design of future clinical studies testing continuous versus
intermittent infusion. If the continuous infusion was required to be initiated shortly
following the loading dose to not delay care, this would have made the design of a
comparative effectiveness trial quite difficult given the short time interval for informed
consent. However, by having this 12-hour window between the start of the next dose,
when administered continuously or intermittently, the logistics of informed consent for
such a trial become much more feasible.
7.6 Strengths and Limitations
When considered in totality, the five aims presented have considerable strengths,
particularly their granular considerations of vancomycin doses and concentrations,
sufficiently powered considering each study’s objective, and rapid ability to translate to
clinical practice should a clinician or institution wish to adopt the particular strategies
studied for precision dosing of vancomycin. While survey techniques and meta-analytic
techniques have their own limitations, the primary limitation from our clinical data,
particularly the pharmacokinetic data obtained in aims 3 and 5, is that they are derived
from a single ICU in a single medical center. Other ICU populations may carry unique
nuances, such as a higher incidence of augmented renal clearance or other
pharmacokinetic alterations, compared with the medical ICU which is primarily a septic
and respiratory failure population. Kentucky is over 85% white,162 and also one of the top
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10 states in the country regarding obesity,163 which in concert with the single center
nature may limit generalizability of these findings to other critically ill patients.
7.7 Future Directions
Critically ill patients have always represented a unique challenge for drugs with
narrow therapeutic indices not only due to the presence of pharmacokinetic changes, but
also the fluctuations that can occur in these patients from day-to-day that may influence
pharmacokinetics. While we did not employ Bayesian forecasting in our aims, our data
from aim 5 and the population pharmacokinetic model we have built serves as
preliminary data to serve as priors in future Bayesian models for continuous infusions of
vancomycin. For a more simplified approach, our simplified dosing nomogram developed
also awaits further validation. While our data from aim 3 demonstrate that an intensive
pharmacokinetic monitoring strategy following the first dose can improve AUC target
attainment at steady state, we anticipate this approach certainly not applicable to every
patient that receives vancomycin and the laborious nature may preclude adoption by
many centers. In the future, if we are able to incorporate our model into a Bayesian
forecasting system, potentially a single level following the initial dose will allow us to
maximize precision dosing of continuous infusion vancomycin in critically ill patients. A
number of other advancements on this front may also allow us to refine dosing
predictions. First, serum creatinine is well-recognized as a poor predictor of renal
function for dosing and assessing AKI, and this was confirmed in our population
pharmacokinetic model where creatine clearance was poorly correlated with estimated
parameters. Serum cystatin C has been shown to predict vancomycin troughs better than
serum creatinine,164 and using this biomarker may allow better refinement of precision
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dosing estimates based on current renal function. Second, real-time glomerular filtration
rate (GFR) assessment using fluorescent molecules allows for continuous monitoring of
GFR which not only has implications for early detection of AKI, but also for potential to
incorporate into precision dosing strategies.165 Microsampling techniques are also being
developed that would minimize the invasiveness and labor associated with blood draws
during therapeutic drug monitoring, which may allow for more frequent monitoring of
vancomycin levels. In addition to the typical challenges of developing these technologies
such as blood-plasma correlation, they need to be validated in critically ill patients
specifically given shunted blood flow.166
While vancomycin stewardship is undoubtedly an important area of clinical focus
to reduce unnecessary vancomycin exposure, our ability to optimize dosing for those who
need it, particularly early in therapy, as well as protect the most vulnerable patients from
further, significant kidney insults, demands that we optimize not only the dose and
exposure, but the method of administration of vancomycin to minimize harm and
promote efficacy.
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APPENDICES
APPENDIX 1. Vancomycin Dosing Practices Survey
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APPENDIX 1 (con)
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APPENDIX 1 (con)
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APPENDIX 1 (con)
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APPENDIX 1 (con)
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APPENDIX 2. First-Order Equations for Vancomycin Pharmacokinetic Calculations
Patient-Specific Pharmacokinetic Parameters From First Dose
1. Step 1: Calculate patient-specific elimination rate (k).

𝑘𝑘 =

ln(

𝐶𝐶1
)
𝐶𝐶2

C1 = 1st random ~2 hours following completion of infusion

𝑇𝑇′

C2 = 2nd random ~12 hours following completion of infusion
T’ = time between C1 and C2

2. Step 2: Calculate half-life (t1/2).
𝑡𝑡1/2 =

ln(2)
𝑘𝑘

3. Calculate Cmax:
𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 =

𝐶𝐶1
−𝑘𝑘(𝛥𝛥𝛥𝛥)
𝑒𝑒

C1 = 1st random ~2 hours following completion of infusion
ΔT = time between C1 and end of the infusion

4. Calculate volume of distribution (Vd)
𝑉𝑉𝑑𝑑 =

𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑡𝑡

1−𝑒𝑒 −𝑘𝑘𝑘𝑘

𝑥𝑥 𝑘𝑘 𝑥𝑥 𝐶𝐶

𝑚𝑚𝑚𝑚𝑚𝑚

t= infusion time

5. Calculate Clearance (Cl)
𝐶𝐶𝐶𝐶 = 𝑘𝑘 𝑥𝑥 𝑉𝑉𝑑𝑑

6. Calculate total daily dose (TDD)
𝑇𝑇𝑇𝑇𝑇𝑇 = 𝐶𝐶𝐶𝐶 𝑥𝑥 𝐴𝐴𝐴𝐴𝐴𝐴𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔

AUC goal = 400-600 (use 500 in calculations)
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APPENDIX 2 (con)
If not using first-dose kinetics:
1.) k is estimated by using the creatinine clearance (CrCl) [Cockcroft-Gault or SalazarCorcoran if > 125% of ideal body weight] and the following equation: k = 0.00083 (CrCl)
+ 0.0044
2.) Vd is estimated using 0.7 L/kg based on actual body weight
Calculating Intermittent Infusion
1. Calculate Dosing Interval (τ)
𝜏𝜏 =

𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
)
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

ln(

𝑘𝑘

+t

Cmax, desired: 40 mcg/mL
Cmin, desired: 10 mcg/mL
t = infusion time

2. Calculate the Maintenance Dose (MD)
𝑀𝑀𝑀𝑀 =

𝑇𝑇𝑇𝑇𝑇𝑇
24
𝜏𝜏

3. Calculate predicted Cmax based on MD and τ selected.

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚

𝑀𝑀𝑀𝑀
𝑉𝑉𝑑𝑑
=
1 − 𝑒𝑒 −𝑘𝑘 𝜏𝜏

4. Calculate predicted Cmin based on Predicted Cmax.
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 𝑥𝑥 𝑒𝑒 −𝑘𝑘(𝜏𝜏−𝑡𝑡)
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t= infusion time

APPENDIX 2 (con)
Evaluating AUC of Intermittent Infusion at Steady State
Step 1. Calculate k

𝑘𝑘 =

𝐶𝐶𝑠𝑠𝑠𝑠
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

𝑙𝑙𝑙𝑙 𝑠𝑠𝑠𝑠
𝐶𝐶

𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡ℎ

T’ = Determined by subtracting the time difference b/t Cpk and Ctr

𝑇𝑇′

from τ

Step 2. Calculate half-life
ln(2)
𝑘𝑘

𝑡𝑡1/2 =

Step 3. Calculate Cmax and Cmin from Cpeak and Ctrough, respectively.
𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 =

𝐶𝐶𝑝𝑝𝑝𝑝

t’= time between Cpk as drawn and end of the infusion

𝑒𝑒 −𝑘𝑘𝑘𝑘′

𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 = 𝐶𝐶𝑡𝑡𝑡𝑡 𝑥𝑥 𝑒𝑒 −𝑘𝑘𝑘𝑘′

t’ = time between Ctr as drawn and true Cmin

Step 4. Calculate Vd
𝑉𝑉𝑑𝑑 =

𝑀𝑀𝑀𝑀
𝑡𝑡

x 𝑘𝑘(𝐶𝐶

(1−𝑒𝑒 −𝑘𝑘𝑘𝑘 )

𝑚𝑚𝑚𝑚𝑚𝑚 )� 1−𝑒𝑒

Step 5. Calculate Cl

t= infusion time in hours

−𝑘𝑘𝑘𝑘 �

𝐶𝐶𝐶𝐶 = 𝑘𝑘 𝑥𝑥 𝑉𝑉𝑑𝑑

Step 6. Calculate AUC

𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 =

(𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 +𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 )

𝐴𝐴𝐴𝐴𝐴𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =

2

𝑥𝑥 𝑡𝑡

t= infusion time

𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 − 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚
𝑘𝑘

24

𝐴𝐴𝐴𝐴𝐴𝐴0−24 = (𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 + 𝐴𝐴𝐴𝐴𝐴𝐴𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 ) 𝑥𝑥 ( 𝜏𝜏 )
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